A RESOURCE submission:

High-throughput phenotyping reveals expansive genetic and structural underpinnings of immune variation

Lucie Abeler-Dörner[1,2], Adam G. Laing [1,2,3], Anna Lorenc[1,2,3], Dmitry S. Ushakov[2,3], Simon Clare[4], Anneliese Speak[4], Maria Duque[4], Jacqui K. White[4], Ramiro Ramirez-Solis[4], Namita Saran[2], Katherine R. Bull[5], Belén Morón[6], Jua Iwasaki[7], Philippa R. Barton[8], Susana Caetano[2,4], Keng I. Hng[2], Emma Cambridge[4], Simon Forman[9], Tanya L. Crockford[5], Mark Griffiths[4], Leanne Kane[4], Katherine Harcourt[4], Cordelia Brandt[4], George Notley[4], Kolawole O. Babalola[10], Jonathan Warren[10], Jeremy C. Mason[10], Amrutha Meeniga[10], Natasha A. Karp[4], David Melvin[4], Eleanor Cawthorne[5], Brian Weinrick[11], Albina Rahim[12], Sibyl Drissler[12], Justin Meskas[12], Alice Yue[12], Markus Lux[12], George Song-Zhao[6], Anna Chan[2], Carmen Ballesteros Reviriego[4], Johannes Abeler[13], Heather Wilson[4], Agnieszka Przemska-Kosicka[2], Matthew Edmans[6], Natasha Strevens[3], Markus Pasztorek[2], Terrence F. Meehan[9], Fiona Powrie[13], Ryan Brinkman[12], Gordon Dougan[4], William Jacobs Jr[11], Clare Lloyd[7], Richard J. Cornall[5], Kevin Maloy[6], Richard Grencis[9], Gillian M. Griffiths[8], David Adams[4], and Adrian C. Hayday[2,3,15]

[1]These authors contributed equally to this work

[2]Department of Immunobiology, King's College London, UK

[3]The Francis Crick Institute, London, UK

[4] Wellcome Sanger Institute, Hinxton, UK

[5]MRC Human Immunology Unit, University of Oxford, UK

[6] Dunn School of Pathology, University of Oxford, UK

[7]Imperial College London, UK

[8] University of Cambridge, UK

[9] University of Manchester, UK

[10]European Bioinformatics Institute, Hinxton, UK

[11] Albert Einstein College of Medicine, New York, US

[12] University of British Columbia, Vancouver, Canada

[13] Department of Economics, University of Oxford, UK

[14]The Kennedy Institute of Rheumatology, University of Oxford, UK

[15]corresponding author

ABSTRACT

By developing a high-density murine immunophenotyping platform compatible with high-throughput genetic screening, we have established profound contributions of genetics and structure to immune variation. Specifically, high-throughput phenotyping of 530 knockout mouse lines identified 140 monogenic "hits" (>25%), most of which had never hitherto been implicated in immunology. Furthermore, they were conspicuously enriched in genes for which humans show poor tolerance to loss-of-function. The immunophenotyping platform also exposed dense correlation networks linking immune parameters with one another and with specific physiologic traits. By limiting the freedom of individual immune parameters, such linkages impose genetically regulated "immunological structures", whose integrity was found to be associated with immunocompetence. Hence, our findings provide an expanded genetic resource and structural perspective for understanding and monitoring immune variation in health and disease.

Because immune function is increasingly implicated in almost every arena of pathophysiology, there is growing demand for more insight into the basis of inter-individual immune variation and for incisive ways to measure it at steady-state and in response to challenges and treatments. Reflecting this are many highly informative studies describing human immune system dynamics[1-4], and investigations of the factors contributing to it[5-8]. Thus, SNP-based and deep sequencing-based Genome-Wide Association Studies (GWAS) and Twin-studies have made compelling associations of defined genetic loci with autoimmunity and/or immunodeficiency[9-14]. However, there has been much discussion of the difficulties of directly linking specific genes and/or genetic variants to discrete immunophenotypes[15]. Conversely, concrete links between specific genes and immune function have emerged from the analysis of Mendelian traits, an approach that is expanding through genome sequencing of many "rare diseases"[16,17]. Nonetheless, this approach can be limited by the infrequency of diseases, uncertain clinical annotation, and limitations on the phenotypic breadth that can be characterized.

At the same time, it has become clear that sex, age, and environmental factors, including diet and the microbiome, make major contributions to human immune variation[5,6,8], but assessing their full impacts is limited by appropriate constraints on interventions, and by the genetic diversity of human populations. In sum, there are so many diverse immunoregulatory factors that it becomes difficult to understand to what degree and by which means any single factor impacts upon the immune system.

In this regard, animal model studies offer unique opportunities, despite the limitations on their extrapolation to human pathophysiology. Specifically, use of an inbred strain limits genetic variation; co-housing reduces microbiome and dietary variation; and the use of age-matched animals limits physiologic variation. By this means, their study can establish a template for the nature and sources of variation in the "baseline immune system", thereby directly informing myriad investigations of rodent immunology and usefully guiding the design and interpretation of human immune system studies.

Added to this, a high-throughput genetic screen of co-housed, age-matched mice could provide clear insight into the fraction of genes whose loss-of-function perturbs one or more

aspects of the baseline immune system, and the nature and functional consequences of those perturbations. Such insight could be expected to reveal novel pathways and forms of immunoregulation relevant to myriad discrete endophenotypes (e.g. prevalence or activity of a defined immune cell type), which can be extremely useful in linking genetic variants to disease[15]. By better depicting the basis and nature of immune variation, such insight could also guide the development of more incisive, practical approaches to immune monitoring. Furthermore, because many diverse phenotypes can be measured in mice, the opportunity exists to relate immune variation to discrete physiologic traits.

To achieve these goals at scale, we have developed a robust, routinely applicable, high-density, high-throughput Infection and Immunity Immunophenotyping ["3i"] platform (www.immunophenotype.org) that has in under 5 years permitted the analysis of the baseline immune system and response to challenge in 530 isogenic, aged-matched, co-housed mutant mouse strains. Additionally, by integrating 3i into the International Mouse Phenotyping Consortium (IMPC) pipeline (www.mousephenotype.org), immune variation could be related to many measures of general physiology.

The expansive outputs of this experimental approach (>1million data-points) have provided several discrete insights and data-rich resources that collectively offer a revised frame-of-reference for viewing immune variation. Specifically, we found that variation in the baseline immune system was contributed to differentially by discrete immune subsets, many of which showed overt sexual dimorphism. Furthermore, variation in specific baseline immune parameters was commonly correlated, positively or negatively, with variation in other immune parameters. While some such correlations were expected, many were not. Additionally, variation in specific immune subsets also correlated with variation in specific, non-immune, physiological traits such as HDL-cholesterol or fructose. By inevitably limiting the freedom-of-movement of any single immune parameter, such correlations must ordinarily impose structural constraints on immune variation.

Of the 530 genes screened, the baseline immunophenotype and/or responses to challenge were affected by mutations in 140 (>25%) genes [a.k.a. "hits"]. Of note, 57% of hits were not hitherto implicated in immunobiology, and yet they were strikingly enriched in genes for

which humans show little tolerance of loss-of-function. Hence, 3i has greatly expanded the number and diversity of genes implicated in immune system biology, with effects ranging from impacts on single parameters to broad immune dysregulation. Furthermore, genes whose mutation affected several immune subsets could be classified into those that substantially preserved the correlations between immune subsets *versus* those that largely disrupted the resulting structures. Interestingly, genes that affected immune and non-immune traits caused significantly greater structural disruption than did genes that only affected immune traits. Moreover, greater disruption was also caused by those genes affecting challenge responses as well as the baseline immune system, thereby associating the integrity of immune structures with host defense. Hence, immunological structure can be an important consideration in the design of immune monitoring.

Results

Immunophenotyping of mutant mice at scale

The goal of the International Mouse Phenotyping Consortium (IMPC) (www.mousephenotype.org) has been to generate and provide open-access phenotyping data for mice with targeted disruptions in each of ~18,000 annotated protein-coding genes, obtained using embryonic stem cells generated by the International Knockout Mouse Consortium[18] and, more recently, using CRISPR technology. As a major contributor to IMPC, the Wellcome Trust Sanger Institute (WTSI) generated approximately three new mutant lines per week. Given this scale, immunological assays performed by IMPC were limited to peripheral blood lymphocytometry and responses to *Salmonella* and *Citrobacter* infection[19] (**Fig 1A; Fig S1A**), inevitably failing to score many genes contributing to immune variation. Therefore, a high-density infection and immunity immunophenotyping platform (3i) was developed (**Fig 1A**) to be compatible with the IMPC high-throughput screen (HTS). At one and the same time, this offered the potential to greatly expand the number and diversity of genes implicated in immunobiology, and to provide a better estimate of the fraction and types of genes that may underpin immune variation. Moreover, by integration into the IMPC, 3i could relate immunophenotypes to many non-immunological traits.

At homeostasis, the baseline immune system is simultaneously poised to respond to infectious or toxic challenges and regulated to limit immunopathology. Hence, inter-individual variation in this state is likely manifest in differential immunocompetence and susceptibilities to autoimmune diseases. To capture this, a high-content flow cytometry analysis of lymphoid and myeloid cells and their activation states in spleen (SPL), mesenteric lymph nodes (MLN), bone marrow (BM) and peripheral blood (PB) was performed at steady-state (**Fig 1A;** panels in **Table S1**; populations quantitated in **Table S2**; illustrative gating strategy for MLN T, NKT, and NK cell subsets shown in **Fig S1B**; gating strategies for all other panels shown in **Fig S4**). To sample the immune system in an extra-lymphoid tissue, quantitative object-based imaging was applied to intra-epidermal lymphoid and myeloid cells *in situ* (**Fig S1C**). Anti-nuclear antibodies (ANA) were quantitated since they commonly reflect impaired immunological tolerance (**Fig S1D**), while effector potential was gauged by measuring cytolysis by SPL CD8 T cells.

To be compatible with the IMPC, immunological assays could not divert tissue from, or operationally impinge upon the basic phenotyping programme. Thus, all observational assays requiring sacrifice were conducted at the prescribed termination-point for IMPC assays of 16 weeks. In parallel, mice were assayed for responses to infection by a parasite (*Trichuris muris*), a virus (influenza), and a bacterium (*Salmonella typhimurium*), and to sodium dextran sulphate (DSS) that causes gut epithelial erosion and microbial translocation (**Fig 1A**; **Fig S1E**). For each component of 3i, experimental standard-operating procedures were established and stringently quality-controlled; instruments were well calibrated; and data reproducibility monitored longitudinally, with automated analysis accounting for any temporal variation (**Fig S1F**; see **Materials and Methods**). Additionally, and to be compatible with the time-and-budget constraints of an HTS, we chose minimum numbers of data-points required to establish significance following application of bespoke statistical analyses (**Fig 1A; Table S3**).

This study reports on the first five-year phase in which 3i phenotyped 530 mutant mouse strains (**Table S4**; see also www.immunophenotype.org): most were knockouts/nulls or severe hypomorphs of protein-coding genes, whereas 1.8% were lncRNA/miRNA mutants. For 30% of the genes, heterozygotes were screened because homozygotes were embryonically lethal or sub-viable. Of the genes selected, ~30% were chosen because they were linked to a disease, e.g. by GWAS, whereas to maximize discovery, the majority were mostly little-studied genes chosen either randomly or guided by investigators' interests.

Overall, >1 million data-points were collected from 7 distinct steady-state assay systems applied to 2,100 -10,000 mice (**Fig 1A**), while several thousand additional mice were subjected to challenges. Of note, the minimization of technical variation; fastidious control for batch variation; optimization of data collection and analysis[20]; and innovative data management across heterologous platforms permitted 3i to make rigorous assessments of naturally-arising variation in the baseline immune system of many hundreds of genetically identical, age-matched, co-located, adult wild-type (wt) "control" C57.BL/6N mice, thereby creating a precise backdrop for the analysis of mutants.

Immunophenotypic variation among controls

Most steady-state immune cell subsets in adult C57.BL/6N controls showed low coefficients of variation (CV), although these were further reduced by dynamic automated gating of flow cytometry data, particularly for numerically small cell subsets whose reproducible quantitation can be challenging (**Fig S1G**). Hence, automated gating was adopted screen-wide to obtain population sizes and CVs (**Figs 1B;** see **Materials and Methods**)[20]. This revealed greater variation for some specific cell types, including germinal centre (GC) B cells and various αβ and γδ T cell subsets expressing the activation marker KLRG1 (**Fig 1B**, bottom-most panel). Activation-driven variation of adaptive immune subsets was anticipated since non-heritable, antigen receptor gene rearrangements dictate different responses of syngeneic individuals to shared environments. Nonetheless, the effects were highly selective, as evidenced by low CVs of KLRG1$^+$ CD4 T helper cells and of KLRG1$^+$ Treg cells compared to a comparably-sized subset of KLRG1$^+$ CD8 T cells (**Fig 1B**, compare top and bottom-most panels for subsets denoted with blue arrows).

Most innate immune subsets showed relatively low CVs, although SPL and PB neutrophils were exceptions, particularly in male mice. Indeed, sex was a consistent source of variation for ~50% of PB, SPL, BM, and MLN cell subsets, reflected in either significantly different variance for female (F) and male (M) mice, as illustrated for PB neutrophils (**Fig 1C**; left panel) and displayed broadly in **Fig 1B** (bottom panel - CV^F, blue circles; CV^M, orange circles), and/or in sexually dimorphic mean values, as illustrated for BM B cell progenitors (**Fig 1C**; right panel), and displayed broadly in **Fig 1B** (middle panel; $mean^F/mean^M$ log2-transformed). Indeed, the impact of sex was so profound that principal component analysis (PCA) of sixty aggregated SPL, MLN, BM, and PBL flow cytometry parameters was sufficient to sex-segregate 451 mice with >99% accuracy (**Fig 1D**).

Cell counts and several other properties of Vγ5$^+$ dendritic epidermal T cells (DETC) and Langerhans Cells (LC) were also significantly sexually dimorphic, as were ANA outputs, evoking the frequent gender imbalance of human autoimmunity (**Fig S1H)**[21]. Conversely, DSS outputs did not segregate significantly by sex, possibly germane to gender-neutral incidences of inflammatory bowel disease (**Fig S1H**)[22]. In sum, the baseline immune system of adult C57.BL/6 mice, the most frequently used strain in immunological investigations, showed

widespread but highly selective sexual dimorphism. As a practical response to this, all statistical tests of 3i data accounted for sex (see **Materials and Methods**).

Significant correlations of discrete immune parameters

Although the immune system clearly comprises a dynamic, multi-component ecosystem, the inter-connectedness of its constituent cell populations is poorly understood. In this regard, the 3i analysis of >650 age-matched, co-located, genetically identical control mice identified significant positive (red) and negative (blue) correlations, as illustrated for 46 steady-state SPL parameters in male and female mice (**Fig 2A**; **Fig S2A**): note, we excluded contingent relationships reflecting nested or paired technical correlates (see **Fig S1B; Fig S4)**.

As illustrated by the male and female SPL data-sets (**Fig 2A**, **Fig S2A**), correlations fell mostly into three classes, of which the first related to activation state. Thus, a "lymphoid activation-cluster" embraced effector $CD4^+$, $CD8^+$, NK and $\gamma\delta$ T cells; Tregs; conventional DC; and plasma cells (**Fig 2A**, **Fig S2A**; central red core). Some such relationships were anticipated: e.g. effector Th correlated with total Treg, and even better with effector Treg. Conversely, other correlations were unanticipated; e.g. effector $CD8^+$ T cells correlated positively with plasma cells (**Fig 2A**, 27 down, 23 across) but negatively with effector NK cells (**Fig 2A**, 27 down, 9 across). Such relationships have implications for the design and monitoring of vaccines aimed at eliciting discrete effector responses.

A second class of correlations related to immune homeostasis. For example, higher NK cell representation reflected increases in mature NK cells (**Fig 2A**, 5 down, 9 across), whereas higher $CD8^+$ T cell representation reflected increases in resting but not effector $CD8^+$ T cells (**Fig 2A**, 45 down *versus* 46 across or 27 across). Finally, a third class of correlations comprised relationships not easily attributable to current knowledge: e.g. significant positive relationships of monocytes with B1 B cells, and of memory B cells with $\gamma\delta$ T cells (**Fig 2A**, 34 down, 20 across; 18 down, 16 across). Exploring the basis of such relationships offers new avenues for immunological investigation.

Highlighting their robustness, many of the identified relationships were largely comparable in male and female mice (**Fig 2A**, **Fig S2A**; **colorless** circles along the 45° axis in **Fig 2B**).

Nonetheless, some parameter pairings were sexually dimorphic, with R values and/or regression slopes being stronger in females (e.g. macrophages *versus* resting NK) or *vice versa* (e.g. monocytes *versus* neutrophils) (**Fig 2B**, purple and orange circles, respectively). Whereas the spleen matrices shown are intra-organ, there were likewise many inter-organ correlations (see below), collectively revealing the baseline immune system of adult C57.BL/6 mice to be underpinned by dense, sexually dimorphic networks of >1000 correlations. Possibly these reflect robust intercellular circuitry, as was recently illustrated for macrophages and fibroblasts[23].

Integrating immunology with physiology

By coupling 3i to the IMPC, all animals in the observational screen were subject to measures of general physiology (see **Figs 1A; S1A**). As is well established, many such measures exhibited positive or negative correlations with each other, which by limiting the freedom-of-movement of individual parameters, imposed dimorphic phenotypic structures for female and male mice that reflect sex-specific physiologies (**Fig S2B**). Of note, the correlation network appeared much less dense in females, possibly because its full elucidation was prevented by the additional variation arising from sex-specific components such as oestrous that cycles every 4-5 days[24]. This notwithstanding, some core relationships were clearly conserved in females and males, e.g. positive correlations spanning cholesterol (Chol), HDL-cholesterol (Hdl), insulin (Ins), and body-weight (Wght), and the relationship of total protein (Tp) to fructosamine (Fruct), which reflects blood protein glycation. Likewise, glucose (Gluc) correlated negatively with chloride (Cl) and sodium (Na). From a practical standpoint, prominent correlations did not simply reflect high dynamic ranges of specific measurements, since Na was among the least variable.

The more consistent variation of non-immunological parameters in males *versus* females allowed us to identify many highly significant correlations between those non-immunological parameters and specific immunological parameters, with Chol, Hdl, and Na again being prominent (**Fig 2C**). Although immunoregulatory roles for metabolic products and processes are well documented[25,26], the correlations identified here were conspicuously selective: thus, there was no overt immunophenotypic correlation with triglycerides, creatinine, or calcium. Interestingly, many correlations were with red blood cell distribution width (Rdw), a common

marker of anaemia[27], frequently associated with chronic immune activation[28,29], and recently shown to predict all-cause mortality in humans[30].

Among immune components, $CD8^+$ T cells displayed 40 statistically significant correlations in male mice, compared to 26 for Tregs; 20 for granulocytes, including blood neutrophils; 10 for NK cells; 8 for $CD4^+$ T cells (excluding Tregs); and 4 for γδ T cells. These correlations offer insights into physiologic and environmental factors, such as hormones and diet, that may regulate specific immune subsets, and may additionally provide practical surrogate measures of immune status.

Clearly, significant correlations of immune parameters with one another and with discrete non-immunological traits will limit the freedom-to-vary of any single immune parameter, thereby imposing an immunological structure, as shown for males (**Fig 2C**). Because of the sparse correlation network of non-immunological parameters in female mice, a comparable immunological structure was harder to discern (**Fig S2A**; lower panel). Nonetheless, an outline structure emerged, within which Hdl, Rdw and Na were again prominent (**Fig 2C**). Indeed, immunological structure may reflect an important balance of immune and non-immunological components that delivers immunocompetence while limiting immunopathology.

Many diverse genes affect the immunophenotype

The establishment of robust ranges for myriad immune parameters across age-matched, co-located, wt control mice, coupled with the application of bespoke statistical tests (see **Figs 1A**; **S1F**; **Table S3**; **Materials and Methods**) facilitated high-throughput screening of 530 mutant lines for "phenodeviants" ("hits") that exerted monogenic dysregulation of the immunophenotype (**Fig 3**). For steady-state immune parameters, phenodeviants were called when ≥60% of samples from a strain located outside the 95th percentiles of the wt distribution for that parameter. To further limit any residual potential for batch effects, each mutant strain was assayed on $\geq$2 separate occasions, with hits called in a supervised manner (i.e. no data-points were discarded but those possibly attributable to a batch effect would not be scored). False positive rates (FPRs) for each parameter were estimated by randomly sampling sets of wt controls in accordance with the real work flow so as to mimic 10,000 different

mutant strains, and then assessing their phenodeviance (**Fig S3A-D**). The resulting FPRs were far below the observed hit-rates that collectively identified 140 phenodeviants, an overall hit-rate of >25% (**Fig S3**). Approximately ~20% of the hits were heterozygotes, that collectively accounted for ~30% of the strains analysed; hence, the hit-rate for heterozygotes was ~18%.

Overall hit-calling by 3i was conservative (**Table S3**). Also, strictly sexually dimorphic phenodeviants would not often have scored because with the exceptions of PB cytometry and ANA, the number of mutant mice examined was too small. Nonetheless, sexually dimorphic trends were apparent, for example, in the TCR$\alpha\beta^+$ CD8 T cell percentages in *Arpc1b*$^{-/-}$ mice; in TCR$\alpha\beta^+$ Treg percentages in *Setd5*$^{-/-}$ mice; and in the TCR$\alpha\beta^+$ CD4$^+$ CD44$^+$ CD62L$^-$ effector T cell percentages which are much lower in male *Il27*$^{-/-}$ mice (see www.immunophenotype.org).

Because most phenodeviants scored in only one or few assays (**Fig 3**), 3i might also have identified more hits if more immunological assays had been performed. For example, no direct assessments of immunological memory were made, and the steady-state gut could not be analysed because of interference with IMPC phenotyping. Thus, a 25% hit-rate may under-estimate the potential contribution of genetics to immune variation. Moreover, no thorough analysis of the likely genetic impact of non-coding regions, e.g. enhancers, was made.

Conversely, the hit-rate might have been slightly inflated because ~30% of genes were chosen based on GWAS and/or other implications in immunobiology. Arguing against this however, the hit-rate for little-studied genes was 23% (103/444), closely comparable to all genes; indeed, 3i identified monogenic impacts on the C57.BL/6 immune system of 80 genes never hitherto implicated in immunoregulation. Phenodeviants embodied diverse functions and potentials, collectively ranging from effects on single endophenotypes to very broad perturbations of the immunophenotype. Illustrating this are four case-studies, briefly considered below (**Figs 4, 5**). Note, however, that detailed data on all phenodeviants are provided at www.immunophenotype.org).

Different classes of genetically regulated immune variation

Nacc2 (Nucleus accumbens-associated protein 2) is a barely-studied gene[31] whose highly specific immunological impact was on Vγ5$^+$ DETC numbers (**Fig 4A**,**B**), a phenotype hitherto observed in C57.BL/6 mice only if they were mutant for Vγ5 or for *Skint* genes that encode poorly understood, epithelial, DETC-selecting elements[32,33]. Thus, the 3i screen identified a novel immune regulator that may offer insight into the mechanism by which *Skint* gene-products select and/or maintain a signature tissue-resident T cell compartment.

Dph6$^{-/-}$ mice displayed an immune-specific but broad phenotype, with several innate and adaptive cell lineages showing significant differences from wt (**Fig 4A**,**C**). Interestingly, *Dph6* is ubiquitously expressed, encoding one of seven enzymes required for synthesizing diphthamide, a modified histidine residue incorporated into eukaryotic elongation factor 2[34]. However, whereas *Dph1, 3* or *4* deficiencies are embryonically lethal[35,36], the 3i phenotype suggested that *Dph6* contributes to a previously unreported aspect of immune cell-specific protein translation that is differentially critical for discrete leukocyte subsets. This is germane to growing evidence that cell type-specific translation can be a profound immunoregulator[37].

In the third case, the broad phenotypic perturbation of several physiologic traits in *Duoxa2*$^{-/-}$ mice (**Fig 5A**) was unsurprising given that Duoxa2 contributes critically to iodine utilisation in thyroid hormone synthesis[38]. By contrast, because, the gene was not hitherto implicated in immunobiology, the significant expansions of specific immune cell subsets, particularly CD4$^+$ αβ T cells, neutrophils and eosinophils, and the decreased representation of blood Ly6C$^-$ monocytes and KLRG1$^+$ NK cells in *Duoxa2*$^{-/-}$ mice were unanticipated (**Fig 5B**). Thus, 3i offers a foundation for exploring how immune variation may be influenced by *Duoxa2*-dependent endocrine effects.

Fourthly, *Bach2*$^{-/-}$ mice illustrated how 3i could offer broader perspectives for viewing a well-established, disease-related gene. Thus, *BACH2* deficiencies have been widely associated with autoimmunity, inflammation, and allergy, with such associations being commonly attributed to increased effector CD4$^+$ and CD8$^+$ T cells, as reported for *Bach2*$^{-/-}$ mice[39-43]. In addition, however, the 3i platform identified a greatly expanded range of innate and adaptive immune phenotypes of *Bach2*$^{-/-}$ mice (orange bars in **Fig 5C**), of which the most significant was a >10-

fold increase in KLRG1^{+}CD4^{-} NK cells (p=0.000000011; reference range combined with Fisher's exact test). These findings collectively suggest that some components of *Bach2*-dependent disease might also reflect precocious innate immune cell activation. Further broadening the perspective on *Bach2* were an abnormally high cytolytic activity of *Bach2*$^{-}$ CD8^{+} T cells, and a high susceptibility of most *Bach2*$^{-/-}$ mice to DSS-colitis (**Fig 5D**, **E**).

Genetic regulators of challenge responses

Of 86 phenodeviants affecting steady-state PB, SPL, MLN, BM or epidermal phenotypes, ~25% also affected responses to challenges, as judged against wt controls assayed contemporaneously. Again, the hits included several sparsely-studied genes (**Fig 6A**, green circles in upper-right quadrant). The fraction of phenodeviants affecting steady-state responses that also affected challenge responses might have been higher if additional challenges and/or assays of response had been employed. However, given the breadth of challenges utilized, and the biologically significant post-challenge outcome measurements (e.g. survival; weight-loss), it is equally likely that genetic redundancy in immune function exceeds that in the baseline immunophenotype. This would predict that genes affecting challenge outcomes should be enriched in those perturbing more than one steady-state parameter, which was indeed the case (**Fig 6A**; larger circles are relatively enriched in upper-right quadrant *versus* lower-right). The prospect of high functional redundancy would ensure that immunocompetence was sustained across a wide range of inter-individual variation in immune cell subsets, as appears to be the case in humans[1-3].

Some phenodeviants, including many sparsely-studied genes, affected functional responses without affecting steady-state immune parameters (**Fig 6A,** upper-left quadrant; see also **Fig 3**). Possibly such gene(s) affect baseline immune parameter(s) not assayed by 3i, while others might reflect gene products which are primarily expressed by non-immune cells and that regulate challenge responses *via* non-immunological mechanisms, e.g. barrier protection. By identifying such genes, the 3i platform offers routes for investigating diverse contributions to host defense.

Given that 57% of the 3i "hits" had never hitherto been implicated in immunobiology, and that the others included many relatively under-studied genes, it was striking that the hits

were collectively enriched in genes for which humans show poor tolerance to "loss-of-function" (LOF). Thus, for 454 genes for which human orthologs had been assessed by the Genome Aggregation Database (gnomAD), there was significantly less LOF tolerance for 3i hits (*n*=119) compared either to those genes that did not score as hits (*n*=335) [p=0.023, Fisher's exact with 0.9 cut-off for LOF[44]], or to all genes based on exomes and genomes from 141,000 individuals[44,45] (**Fig 6B**, upper panel). Of note, LOF tolerance was also low for genes that only affected baseline immune parameters (*n*=53) (**Fig 6B**, lower panel), emphasizing the power of a steady-state endophenotype screen such as 3i to identify genes that are functionally relevant to host fitness.

Consistent with this perspective, the 140 immunological phenodeviants were also strikingly enriched in genes that also had non-immunological phenotypes: 58/140 [>41%] *versus* 91/390 [23%] (p=0.000072). Again, this was true for genes affecting baseline immune variation *versus* those that did not: 39/86 [>45%] *versus* 110/444 [25%] (p=0.00021) (**Fig 6C**). Likewise, relative to the genes that did not score, the 131 phenodeviants with identifiable human orthologs were significantly enriched in genes screened because of GWAS implications (21/131 [16%] *versus* 28/368 [7.6%])(**Fig 6D**). This further emphasizes the capacity of steady-state endophenotypes to inform disease associations, evoking the profound utility of increased B cell counts and reduced monocyte numbers in linking a specific *BAFF* gene variant to multiple sclerosis and lupus[15]. Discrete endophenotypes were likewise scored for seven of nine genes with pre-assigned OMIM immunology-related designation (**Fig 6D**).

In sum, through the identification of baseline and/or post-challenge monogenic endophenotypes, the 3i screen has greatly expanded the number and scope of genes implicated in immunobiology. Moreover, given that ~70% of genes screened were little-studied, it was striking that the 3i endophenotypic screen produced an unbiased enrichment for genes likely to be of human disease-relevance given their low LOF tolerance and/or impacts on general physiologic traits.

Genetic regulation of correlation networks

The 3i data-sets were next used to ask whether genes affecting one or more steady-state immune parameter(s) might segregate according to whether or not they also disrupted the

correlations connecting immune parameters: i.e. whether or not they impacted upon immunological structure. **Fig 7A** (left panel) schematises hypothetical distribution clouds of data-points for three phenodeviants (yellow, pink, green) displaying extreme values for cell population B. Of note, whereas the yellow and green genes maintained proportionality with population A, the pink gene broke that correlation.

Real examples of this are shown in **Fig 7B**: *Gmds* and *Arpc1b* mutants displayed very few NK cells but maintained proportionality with mature NK cells, whereas most *Arhgef1*$^{-/-}$ and *Pclaf1*$^{-/-}$ mice sat outside the confidence limits of the relationship between total and mature NK cells, showing disproportionately high NK maturation. Likewise, *Duxoa2*$^{-/-}$ and *Dph6*$^{-/-}$ mice, whose effector CD4^{+} T cell numbers were atypically low and high, respectively, each preserved an inverse relationship of effector CD4^{+} Th cells and naïve CD8^{+} T cells, whereas this correlation was broken by deficiencies in *Gmds* and *Cog6*. Hence, correlations that confer structure on the immune system can be resilient to one genetic perturbation, but be broken by a different one.

Overall, we observed that genes with the potential to affect $\geq$10 correlates collectively preserved ~75% of intra- and inter-organ correlations (**Fig 7C**; "Total"). Hence, the overriding impression was that immune correlations were relatively resilient to genetic perturbation of discrete immune parameters that can underpin immune variation. Nonetheless, it was inevitably the case that mutations of some genes that affected large numbers of immune parameters were more likely to disrupt substantially more correlations, as was evident for *Cog6* and *Bach2* (**Fig 7C**). This notwithstanding, structural breakage did not simply reflect the number of immunophenotypes affected by any one gene. Thus, most intra-organ and inter-organ correlations of immune cell subsets were preserved in *Dph6*$^{-/-}$ mice which displayed a similar number of steady-state immune parameters (e.g. altered cell subsets) to *Cog6*$^{-/-}$ mice: for example, compare the density of red lines (broken correlations) *versus* blue lines (preserved correlations) in the spleens of the two strains in **Fig7D**. This argues that specific genes underscore the existence of certain correlations and hence underpin immunological structure. Added to this, *Arpc1b* broke many inter-organ correlations while preserving most intra-organ correlations (**Fig 7C**), indicating that different genes regulate immune subset relationships in different ways.

Given that many immune parameters also correlated with specific physiologic measures, thereby composing structures of the kind illustrated in Fig 2C, it was appropriate to ask whether genes with non-immunological phenotypes were more likely to disrupt immunological structure. Indeed, baseline structure seemed much less resilient when discrete physiological traits were also perturbed, with such genes collectively breaking significantly more correlations than were broken by genes only affecting immune parameters: 30% *versus* 16% ($p<0.001$, Probit regression) (**Fig 7E**). Additionally, it was noteworthy that genes which impacted upon challenge responses as well as upon the baseline immunophenotype broke significantly more correlations than did genes affecting only the baseline immunophenotype: 35% *versus* 19% ($p<0.001$, Probit regression) (**Fig 7F**).

The results shown in Figs7E and 7F were robust to controlling for unequal numbers of correlations per gene (non-immune $p<0.001$, challenge $p<0.001$) and to allowing for any dependencies of correlations within a gene by using cluster-robust standard errors (non-immune $p=0.007$; challenge $p=0.021$). Moreover, controlling for the influence of non-immune traits and challenge responses in the same regression analysis confirmed separate contributions of non-immune and challenge phenotypes ($p<0.001$ for non-immune controlling for challenge; $p<0.001$ for challenge controlling for non-immune). Clearly, the association of defects in immunocompetence with compromises to structural integrity in the baseline immune system strongly suggests the importance of immunological structure and makes a compelling case for measuring immune subset correlations as a means to monitor functionally significant immune variation.

Discussion

The development and implementation of the 3i platform has combined genetic screening and immunophenotyping at scale. Thereby, it has established that variation in the immunophenotype can be significantly shaped by genetics, substantially expanding the number and diversity of genes shown to have monogenic impacts on steady-state immune parameters and/or challenge responses. Those findings compose a resource for generating hypotheses to underpin subsequent in-depth studies. The potential value of this is highlighted by recent evidence that baseline endophenotypes can critically aid the causal association of genetic variants with human disease[15]. In this vein, it is noteworthy that 3i's screening mostly of little-studied genes conspicuously enriched for those for which humans show poor tolerance to loss-of-function. Their individual follow-up may expose understudied immunoregulatory pathways that can inform polygenic human diseases where single-gene effects sizes are small. Those pathways will probably include those that act immune cell autonomously and those that act *in trans.*

At the same time, the scale and robustness of 3i, including its minimization of technical and batch variation, has provided insight into the nature and scope of immune variation in one of the community's most-studied animal model, the C57.BL/6N mouse, with comprehensive, in-depth data-sets curated on a sustainable, user-friendly web interface www.immunophenotype.org. In practical terms, the 3i platform also offers protocols by which to quickly obtain broad immunophenotypic data from mice in myriad experimental scenarios. In this regard, it is noteworthy that the relative proportions of cells composing the spleen were recently shown to be as effective an indicator of autoimmune dysregulation as the cells' micro-anatomical localization[46].

The scale and throughput of the 3i screen yielded substantial data-sets supporting the view that the baseline immune system is strongly sexually dimorphic[47,48], but showed that this applied highly specifically. These findings should be accommodated in the design of mouse experiments, and whilst the specifics of sexual dimorphism will differ from mouse to human[48], the findings should likewise be considered in the design of immune interventions and immune-monitoring strategies in humans.

The scale, throughput, and robustness of the 3i screen were also sufficient to reveal dense networks of correlations of immune parameters with themselves and with general physiologic traits. Such correlations will *de facto* impose structures constraining immune variation. Although high-level structure was more evident in males, we believe that similar structures exist in females but is masked by the higher variability in general physiology. Consistent with this, males and females showed comparable frequencies of correlations between immunological parameters.

The correlations charactering the baseline immunophenotypes of male and female C57.BL/6N differ in detail across different organs, and they will inevitably differ across mouse strains and across species. This is not to diminish the importance of the correlations revealed by 3i, since they provide a structural framework for viewing immune variation more generally. For example, immunological structures may sustain balanced immune interactions that to some degree insulate immune function from inter-individual and sexually dimorphic variation. Likewise, the co-ordination of immune cell subsets reflected by immunologic structure may confer agility on the immune system to respond to diverse challenges. This would be entirely consistent with the observation that most phenodeviants in the steady-state failed to impact the challenge responses as measured by 3i, whereas correlations between immune parameters (i.e. the underpinnings of immunological structure) were more frequently disrupted by genes that impaired challenge response(s).

This association of immunological structures with biologically significant outcomes makes a compelling case for including structural metrics (e.g. subset ratios *versus* consensus values) in immune-monitoring strategies. In support of this, *Bach2*, *Cog6* and *Arpc1b* which are strongly associated with human disease, were readily scored by the criterion of disrupting of inter-organ correlations[39-41,49-51]. Moreover, therapeutic responsiveness to checkpoint blockade was recently associated with a ratio of $CD8^+$ T cell subtypes, rather than with subsets viewed individually [52].

Likewise, immune-monitoring strategies might usefully include general physiologic traits, since correlations linking immune parameters were more frequently disrupted by genes that also affected non-immunological parameters. Moreover, while many will vary, some of the

core correlations may be conserved cross-species. For example, the numerous correlations with HDL-cholesterol may be relevant to the established anti-inflammatory impacts of HDL, that have to date been primarily attributed to the down-regulation of TLR-mediated cytokine induction[53]. Likewise, the many immunological correlations with Rdw were unanticipated but are potentially linked to the recently emerging strength of Rdw as a predictor of all-cause mortality, perhaps reflecting its association with pathologic inflammation germane to cardiovascular disease and cancer[30]. Collectively, the robust correlations revealed by 3i emphasize the need for more intensive studies of how immunology is integrated with specific components of general physiology.

Finally, the density of correlation networks revealed by 3i makes the case for investigating their biological basis. Do they, for example, reflect gene regulatory networks common to the homeostasis of different cell populations, and/or robust intercellular circuitry, as was recently illustrated for macrophages and fibroblasts?[23] Such processes may themselves be regulated by factors such as diet and hormones, reflected by the correlations of immune parameters with discrete physiologic traits. The biological basis of correlation networks may create foundations for better understanding how mutations in specific genes, e.g. *Bach2*, and/or in the super-enhancers that control those genes may provoke severe immunopathology because of their impact on immunological structure[43].

References

1. Nakaya, H. I. *et al.* Systems biology of vaccination for seasonal influenza in humans. *Nat. Immunol.* **12,** 786–795 (2011).
2. Sobolev, O. *et al.* Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. *Nat. Immunol.* **17,** 204–213 (2016).
3. Tsang, J. S. *et al.* Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses. *Cell* **157,** 499–513 (2014).
4. Wei, S. C. *et al.* Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell* 1–32 (2017).
5. Brodin, P. *et al.* Variation in the human immune system is largely driven by non-heritable influences. *Cell* **160,** 37–47 (2015).
6. Carr, E. J. *et al.* The cellular composition of the human immune system is shaped by age and cohabitation. *Nat. Immunol.* **17,** 461–468 (2016).
7. Patin, E. *et al.* Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. *Nat. Immunol.* **19,** 302–314 (2018).
8. Alpert, A. *et al.* A clinically meaningful metric of immune age derived from high-

dimensional longitudinal monitoring. *Nat. Med.* 1–34 (2019).
9. Ellinghaus, D. *et al.* Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat. Genet.* **48,** 510–518 (2016).
10. Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat. Genet.* **47,** 979–986 (2015).
11. Tsoi, L. C. *et al.* Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nat. Genet.* **44,** 1341–1348 (2012).
12. Orrù, V. *et al.* Genetic variants regulating immune cell levels in health and disease. *Cell* **155,** 242–256 (2013).
13. Nelms, K. A. & Goodnow, C. C. Genome-wide ENU mutagenesis to reveal immune regulators. *Immunity* **15,** 409–418 (2001).
14. Wang, T. *et al.* Real-time resolution of point mutations that cause phenovariance in mice. *Proc Natl Acad Sci USA* **112,** E440–E449 (2015).
15. Steri, M. *et al.* Overexpression of the Cytokine BAFF and Autoimmunity Risk. *N Engl J Med* **376,** 1615–1626 (2017).
16. Zhang, S.-Y. *et al.* TLR3 deficiency in patients with herpes simplex encephalitis. *Science* **317,** 1522–1527 (2007).
17. Turnbull, C. *et al.* The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. *BMJ* **361,** k1687 (2018).
18. Skarnes, W. C. *et al.* A conditional knockout resource for the genome-wide study of mouse gene function. *Nature* **474,** 337–342 (2011).
19. White, J. K. *et al.* Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. *Cell* **154,** 452–464 (2013).
20. Rahim, A. *et al.* High throughput automated analysis of big flow cytometry data. *Methods* **134-135,** 164–176 (2018).
21. Cooper, G. S. & Stroehla, B. C. The epidemiology of autoimmune diseases. *Autoimmunity Reviews* **2,** 119–125 (2003).
22. Ananthakrishnan, A. N. Epidemiology and risk factors for IBD. *Nature Publishing Group* **12,** 205–217 (2015).
23. Zhou, X. *et al.* Circuit Design Features of a Stable Two-Cell System. *Cell* **172,** 744–747.e17 (2018).
24. Byers, S. L., Wiles, M. V., Dunn, S. L. & Taft, R. A. Mouse estrous cycle identification tool and images. *PLoS ONE* **7,** e35538 (2012).
25. Huang, S. C.-C. *et al.* Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation. *Immunity* **45,** 817–830 (2016).
26. Kolev, M. *et al.* Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses. *Immunity* **42,** 1033–1047 (2015).
27. Salvagno, G. L., Sanchis-Gomar, F., Picanza, A. & Lippi, G. Red blood cell distribution width: A simple parameter with multiple clinical applications. *Crit Rev Clin Lab Sci* **52,** 86–105 (2015).
28. Olumuyiwa-Akeredolu, O.-O. O. & Pretorius, E. Platelet and red blood cell interactions and their role in rheumatoid arthritis. *Rheumatol. Int.* **35,** 1955–1964 (2015).
29. Periša, V. *et al.* Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. *Croat.*

Med. J. **56,** 334–343 (2015).
30. Pilling, L. C., Atkins, J. L., Kuchel, G. A., Ferrucci, L. & Melzer, D. Red cell distribution width and common disease onsets in 240,477 healthy volunteers followed for up to 9 years. *PLoS ONE* **13,** e0203504–12 (2018).
31. Xuan, C. *et al.* RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene. **32,** 3711–3721 (2012).
32. Barbee, S. D. *et al.* Skint-1 is a highly specific, unique selecting component for epidermal T cells. *Proc. Natl. Acad. Sci. U.S.A.* **108,** 3330–3335 (2011).
33. Narita, T., Nitta, T., Nitta, S., Okamura, T. & Takayanagi, H. Mice lacking all of the Skint family genes. *International Immunology* **30,** 301–309 (2018).
34. Liu, S. *et al.* Diphthamide modification on eukaryotic elongation factor 2 is needed to assure fidelity of mRNA translation and mouse development. *Proc. Natl. Acad. Sci. U.S.A.* **109,** 13817–13822 (2012).
35. Chen, C.-M. & Behringer, R. R. Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. *Genes Dev.* **18,** 320–332 (2004).
36. Liu, S. *et al.* Dph3, a small protein required for diphthamide biosynthesis, is essential in mouse development. *Mol. Cell. Biol.* **26,** 3835–3841 (2006).
37. Jackson, R. *et al.* The translation of non-canonical open reading frames controls mucosal immunity. *Nature* 1–20 (2018).
38. Grasberger, H. & Refetoff, S. Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent. *J. Biol. Chem.* **281,** 18269–18272 (2006).
39. Christodoulou, K. *et al.* Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. *Gut* **62,** 977–984 (2013).
40. Cooper, J. D. *et al.* Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. *Nat. Genet.* **40,** 1399–1401 (2008).
41. Liu, W. *et al.* Identification of BACH2 as a susceptibility gene for Graves' disease in the Chinese Han population based on a three-stage genome-wide association study. *Hum. Genet.* **133,** 661–671 (2014).
42. Roychoudhuri, R. *et al.* BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. *Nature* **498,** 506–510 (2013).
43. Afzali, B. *et al.* BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. *Nat. Immunol.* **18,** 813–823 (2017).
44. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536,** 285–291 (2016).
45. Karczewski, K. J. *et al.* Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes: Supplementary Information. 1–39 (2019). doi:10.1101/531210
46. Goltsev, Y. *et al.* Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. *Cell* **174,** 968–981.e15 (2018).
47. Piasecka, B. *et al.* Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. *Proc Natl Acad Sci USA* **115,** E488–E497 (2018).
48. Zalocusky, K. A. *et al.* The 10,000 Immunomes Project: Building a Resource for Human Immunology. *Cell Rep* **25,** 513–522.e3 (2018).
49. Márquez, A. *et al.* A combined large-scale meta-analysis identifies COG6 as a novel

shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheum Dis* **76,** 286–294 (2017).
50. Liu, Y. *et al.* A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. *PLoS Genet* **4,** e1000041–14 (2008).
51. Kuijpers, T. W. *et al.* Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency. *J. Allergy Clin. Immunol.* **140,** 273–277.e10 (2017).
52. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell* **175,** 998–1013.e20 (2018).
53. De Nardo, D. *et al.* High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. *Nat. Immunol.* **15,** 152–160 (2014).
54. Karp, N. A. *et al.* Applying the ARRIVE Guidelines to an In Vivo Database. *PLoS Biol.* **13,** e1002151 (2015).
55. Karp, N. A., Melvin, D., Sanger Mouse Genetics Project & Mott, R. F. Robust and Sensitive Analysis of Mouse Knockout Phenotypes. *PLoS ONE* **7,** e52410–11 (2012).
56. Karp, N. A. *et al.* Impact of Temporal Variation on Design and Analysis of Mouse Knockout Phenotyping Studies. *PLoS ONE* **9,** e111239–10 (2014).
57. Ryder, E. *et al.* Molecular characterization of mutant mouse strains generated from the EUCOMM/KOMP-CSD ES cell resource. *Mamm. Genome* **24,** 286–294 (2013).
58. Malek, M. *et al.* flowDensity: reproducing manual gating of flow cytometry data by automated density-based cell population identification. *Bioinformatics* **31,** 606–607 (2015).
59. Mason, J. *et al.* Prevalence of sexual dimorphism in mammalian phenotypic traits. *Nat Commun* **8,** 1–12 (2017).
60. Kurbatova, N., Mason, J. C., Morgan, H., Meehan, T. F. & Karp, N. A. PhenStat: A Tool Kit for Standardized Analysis of High Throughput Phenotypic Data. *PLoS ONE* **10,** e0131274 (2015).

Materials and Methods

Contact for Reagent and Resource Sharing

For additional information about reagents and resources, contact Adrian Hayday at adrian.hayday@kcl.ac.uk.

Experimental design

All assays relied on the fastidious application to cells and tissues of intensively piloted, robust, optimised Standard Operating Procedures (SOPs) employing high-resolution, quantitative protocols, whose high reproducibility was monitored over time (e.g. **Fig S1F**).

Mice were randomly allocated to the experimental groups (wt *versus* mutant) by Mendelian inheritance. The experimental unit in the study was the individual mouse. For the majority of tests, operators were blinded with regard to the genetic identities of mice. Further detailed experimental design information is captured by a standardized ontology as described[18], and is available from the IMPC portal <http://www.mousephenotype.org>. The steady-state screens integrated within the HTS followed a multi-batch design, in which a baseline set of control data was constantly collected by phenotyping wt mice of both sexes along with mutant mice at least once per week. As soon as mutant mice from the breeding colonies reached appropriate ages, they were issued to the pipeline until sufficient number of males and females of each genotype were assessed. In this way, animals from each mutant strain were tested on two to five days, interspersed throughout experiment duration, rather than within one batch. For advantages and robustness of such design in an HTS see [19,54-56]. The challenge screens implemented a parallel group study design.

Compliant with HTS practice, the numbers of mice examined in each assay were dictated by costs, logistics, and power, with bespoke statistical tests [see below] applied to identify genes (so-called "hits") perturbing defined components of the immune system. Two to seven homozygote mice of each sex per mutant line were assessed per test. If no homozygotes were obtained from $\geq$28 offspring of heterozygote intercrosses, the line was deemed homozygous lethal. Similarly, if <13% of the pups resulting from intercrossing were homozygous, the line was judged as being homozygous subviable. In either case, heterozygotes were phenotyped. The numbers and sex of animals tested per genotype and assay are summarized in **Supplementary Table 4**.

Ethical compliance

Mouse use in this study was justified based on their facilitating a large variety of phenotypic tests to be carried out on a sufficient number of individuals in a controlled environment. The care and use of mice in the study was conducted in accordance with UK Home Office regulations, UK Animals (Scientific Procedures) Act of 2013 under two UK Home Office

licenses which approved this work (80/2076 and 80/2485) which were reviewed regularly by the WTSI Animal Welfare and Ethical Review Board.

All efforts were made to minimize suffering by considerate housing and husbandry, the details of which are available at the IMPC portal: http://www.mousephenotype.org/about-impc/arrive-guidelines. Animal welfare was assessed routinely for all mice involved. Adult mice were killed by terminal anaesthesia followed by exsanguination, and death was confirmed by either cervical dislocation or cessation of circulation.

Animals

Mice were maintained in a specific pathogen-free unit under a 12hr light, 12hr dark cycle with water and food *ad libitum* (Mouse Breeders Diet (LabDiets 5021-3, IPS, Richmond, USA), unless stated otherwise. Mice where housed in Tecniplast Sealsafe 1284L (overall dimensions of caging (L × W × H): 365 × 207 × 140 mm; floor area = 530 cm^2) at a density of 3-5 animals per cage, and provided with a sterilized aspen bedding substrate and cardboard tubes and nestlets for environmental enrichment.

Mutant mouse production

Mice carrying knockout first conditional-ready alleles were generated on a C57BL/6N background using the EUCOMM/KOMP Embryonic Stem (ES) cell resource, with ES quality control and molecular characterization of mutant mouse strains performed as described previously [57]. Upon completion of phenotyping, genotyping was repeated and data were only accepted from mice for which the second genotype was concordant with the original. The knock-in first strategy first generates mice that still possess the full sequence of the targeted gene, interrupted in a crucial exon by the inserted cassette. These tm1a alleles result in functional knockout lines in most cases, but can carry residual expression of the targeted gene. These tm1a alleles can be converted into unequivocal full knockout tm1b alleles by excising the inserted cassette with the targeted essential exon. Details of alleles used can be found in Skarnes *et al*[18]. All lines are available from www.knockoutmouse.org or mouseinterest@sanger.ac.uk.

Non-immune phenotyping

Non-immune phenotyping (summarized in FigS1A) was conducted as described [19].

Immunological steady-state phenotyping

Tests conducted in the steady-state (PBL, SPL, MLN, BM, ear epidermis, antinuclear antibodies, cytotoxic T lymphocytes function) were conducted on the same 16-week-old mice that were subject to broad non-immunological phenotyping procedures[19]. Non-fasted mice were terminally anaesthetised using Ketamine (100mg/kg)/Xylazine (10mg/kg) injection. Organs were harvested and either analysed directly (PBL) or shipped in HBSS at 4°C. for

analysis on the same day off-site. Readouts of the respective tests and numbers of mice used are summarized in **Fig S1** and **Supplementary Table 3**.

Single cell preparation of immune cells from spleen

After removing the fat, spleens were transferred into Miltenyi C-tubes with 3 ml of enzyme buffer (PBS Ca^{2+}/Mg^{2+}, 2% FCS (v/v), 10mM HEPES, Collagenase (1 mg/ml), and DNAse (0.1 mg/ml). Samples were then processed using a Miltenyi Gentle MACS dissociator (SPL program 01) and incubated at 37°C for 30 minutes. After the incubation, samples were processed again in the Miltenyi Gentle MACS dissociator (SPL program 02) and the enzyme reaction was stopped adding 300µl of stop buffer (PBS, 0.1M EDTA). Samples were filtered through 30µm filters and centrifuged for 5 minutes at 400g at 8°C. The pellet was resuspended in FACS buffer (PBS, Ca^{2-}/Mg^{2-}, 0.5% FCS, EDTA 2mM), incubated for 60 seconds in RBC lysis buffer and then washed with FACS buffer. Samples were transferred to 96-well V bottom plates and incubated in 50µl of RBC lysis buffer (eBioscience) for 1 minute prior to antibody staining.

Single cell preparation of immune cells from mesenteric lymph nodes (MLN)

After removing the fat, MLN were transferred into 1.7ml microfuge tubes with 200µl of buffer (PBS Ca^{2+}/Mg^{2+}, 2% FCS (v/v), 10mM HEPES) and ruptured using small plastic pestles. 400µl enzyme buffer (PBS Ca^{2+}/Mg^{2+}, 2% FCS (v/v), 10mM HEPES), Collagenase (1mg/ml), and DNAse (0.1mg/ml) were and samples were incubated for 15 minutes at 37°C. The reaction was stopped by adding 60µl stop buffer (PBS 0.1M EDTA) and samples filtered through 50 µm filters and centrifuged for 5 min at 400g at 8°C. The cell pellet was resuspended in FACS buffer (PBS Ca^{2-}/Mg^{2-}, 0.5% FCS, EDTA 2mM) and transferred to 96-well V bottom plates for antibody staining.

Single cell preparation of immune cells from bone marrow (BM)

The tibia was cleared of muscle tissue and cut below the knee and above the ankle. The open bone was placed into a cut pipette tip placed into a microfuge tube, thereby keeping the bone away from the bottom of the tube and allowing the bone marrow to be centrifuged out of the bone at 1000 ×g for 1 minute. The bone was discarded and the pellet resuspended in 50µl RBC lysis buffer at room temperature for 1 minute. Cells were washed in 200µl FACS buffer and again centrifuged at 1200 rpm for 1 minute. Cells were resuspended in 400µl FACS buffer and transferred to 96-well V bottom plates for antibody staining.

Blood preparation

Blood was collected into EDTA coated tubes (peripheral blood leukocytes assay) *via* the retro-orbital sinus. Whole blood for peripheral blood leukocyte assays was stained with two titrated cocktails of antibodies (see **Materials and Methods**). Using the white blood cell count

obtained from the haematological analysis, absolute cell counts were derived for each population and reported as cells/µl.

Immunophenotyping by flow cytometry

Single cell suspensions were incubated with Fc-block for 10 min at room temperature, washed 4x, first with FACS buffer and then with PBS, and then incubated with live/dead ZiR dye (biolegend) for 10 minutes at room temperature. Samples were washed again with FACS buffer and incubated with a number of antibody cocktails (see Materials and Methods) at 4°C for 20 minutes. Samples were washed 2x with FACS buffer and measured on a BD Fortessa X-20 equipped with 405nm, 488nm 561nm and 644nm lasers: full details of instrument setup are available at www.immunophenotyping.org. Data were analysed with FACSDiva and Flowjo software. FCS files are available from flowrepository.org.

Flow cytometry quantification (SPL, MLN and BM)

Additionally to the manual gating performed at the time of data acquisition, collected flow cytometry data for SPL, MLN and BM were gated computationally using flowClean, UFO, and flowDensity[20,58]. FlowClean was used to perform acquisition-based quality checking to remove anomalous events. Files with fewer than 20,000 events were then removed from further analysis. UFO was used to identify outlier samples (e.g., batch effects). FlowDensity was used to enumerate cell populations by automating a predefined gating approach using sequential, supervised bivariate gating analysis to set the best cut-off for an individual marker using characteristics of the density distribution. The parameters for each individual cell population were pre-defined once for all files. The automated analysis data was validated against matched manually analysed data. Gating strategies are outlined in **Fig S1B** and in **Fig S4 A-D**).

Ear epidermis immunophenotyping

Epidermal sheets from mouse ears were treated with hair removal cream (Nair) for 4 min at room temperature. After removing the cream by extensive washing in PBS, ears were split into dorsal and ventral sides and incubated dermal side down for 35 min at 37°C in 0.5M ammonium thiocyanate (Sigma-Aldrich). Epidermal sheets were gently peeled from the dermis in PBS, and fixed in cold acetone for 20min at -20°C. After washing in PBS, epidermal sheets were incubated for 1h at room temperature with 5% (wt/vol) FCS in PBS and were stained for 1h at 37°C with Vγ5 TCR-FITC (clone 536; BD), MHCII-AF647 (I-A/IE; BioLegend) and CD45-eFluor450 (eBioscience). Epidermal sheets were washed extensively in PBS and mounted on slides with ProLong Gold antifade medium (Life Signalling Technologies). Leica SP2 or SP5 confocal microscopes equipped with 40x 1.25 NA oil immersion lens and 405 nm, 488 nm and 633 nm lasers were used to record 1024x1024 pixel confocal z-stacks with Leica Acquisition Software. The confocal records were processed and quantified with Definiens Developer XD^{R} software using a custom made automated protocol where images were

smoothed with a sliding window Gaussian pixel filter, segmented by an automated Otsu's method and then filtered based on object size and morphology parameters to detect cells in each fluorescence channel. Further, in order to quantify the number and length of dendrites, the detected cells were skeletonised in 3D to determine the points where dendrites start to branch out of the cell body.

Antinuclear Antibody Immunophenotyping

Murine serum samples were obtained and stored at -20°C prior to analysis (after dilution 1:100 in PBS) by incubating on commercially-sourced substrate slides (A. Menarini Diagnostics Ltd.) coated with HEp-2 cells for 30 minutes at room temperature in a humidifying tray. Samples were removed and slides were washed 2x with PBS for 5 minutes and once with water for 5 seconds. Slides were incubated with FITC-conjugated Goat Anti Mouse IgG, diluted 1:500 and incubated for 20 minutes at room temperature in a humidifying tray in the dark. The secondary antibody was removed and slides washed twice with PBS for 5 minutes and once with water for 5 seconds, both in the dark. Slides were mounted in medium and stored at 4°C prior to imaging for 400ms at 20x magnification in the GFP channel on a Nikon wide-field TE2000U Microscope or a Deltavision Elite widefield system based on an Olympus microscope. Images were subject to multi-parametric analysis in Fiji. Samples were scored from 0-4 according to intensity based on control samples and commercially sourced FITC QC beads. Samples scored ≥2 were marked as ANA positive. All sera flagged by automated image analysis as putative positives *vis-à-vis* a contemporaneous standard were manually cross-checked for *bona fide* nuclear localization before scoring.

Cytotoxic T Lymphocyte Immunophenotyping

Mouse splenocytes were isolated using 70μM cell strainers (BD Plastipak) and cultured in T cell media (TCM: 500ml RPMI, 500μl B-ME, 5ml NaPyr, 5ml pen/strep, 5ml L-glut, 50ml 10% heat inactivated FCS and 100μl IL-2) on 6-well plates pre-coated with 0.5μg/ml αCD3ε and 1μg/ml αCD28 (1.7×10^6 cells/well) for 48 hours. Plates were washed and cells where cultured for a further 8 days with daily passage prior CTL assay.

Cytotoxicity assays were performed using a CytoTox96 Non-Radioactive Cytotoxicity Assay kit (Promega UK Ltd). Cells were washed and re-suspended in killing assay media (KAM: 500ml RPMI-phenol red, 10ml 10% heat inactivated FCS and 5ml pen/strep), with CTLs at a concentration of 0.1×10^6 and P815 target cells at a concentration of $0.1\times10^{6.}$ Purified hamster anti-mouse CD3ε was added to P815 target cells.

P815 cells were added to a serial dilution of CTL samples and incubated for 3 hours. Lysis buffer (Promega UK Ltd.) was added to control samples and incubated for 45 minutes. Supernatants were harvested and substrate mix (Promega UK Ltd) was added prior to a 30

minute incubation in the dark. Stop solution (Promega Corporation UK Ltd) was added to halt the reaction and results acquired using a spectrophotometer (VersaMax, molecular devices).

Flow cytometric analysis was performed to assess the percentage of $CD4^+$ and $CD8^+$ cells within the cell culture. The cell suspension was washed in FACS buffer and the cell pellet re-suspended in a staining master mix (FACS buffer solution + 1:200 anti-CD8α APC and 1:200 anti-CD4 PE). Tubes were then incubated in the dark for 7 minutes at room temperature before the antibody was washed off and cells resuspended in FACS buffer. Results were acquired on a FACS Calibur machine and analysed using FlowJo 10 software.

Challenge screens

Challenge screens were conducted on separate cohorts of mice from the same breeding colony as steady-state screens.

DSS colitis challenge

Colitis was induced by adding 1.5% (w/v) DSS (Affymetrix, Inc.) to drinking water for 7 days, followed by 3 days with regular drinking water, in animals aged between 5 and 18 weeks (mean age 9 weeks). Mice were weighed every day and culled if weight loss reached 20% of starting weight.

For histological assessment of intestinal inflammation, mice were sacrificed at day 10 by cervical dislocation, and samples from mid and distal colon taken. Tissue sections were fixed in buffered 10% formalin; paraffin-embedded; cut; and stained with haematoxylin and eosin. Colon histopathology was blind-graded semi-quantitatively on a scale from zero to three, for four criteria: (1) degree of epithelial hyperplasia/damage and goblet cell depletion, (2) leukocyte infiltration in lamina propria, (3) area of tissue affected, and (4) presence of markers of severe inflammation, including crypt abscesses, submucosal inflammation, and oedema. Scores for individual criteria were added for an overall inflammation score of between zero and twelve for each samplle. Scores from mid and distal colon were then averaged to obtain inflammation scores for each mouse colon.

Salmonella typhimurium challenge

Groups of 8 mutant and 8 C57BL/6N wild type mice were challenged intravenously with 5 x 10^5 colony forming units (cfu) *Salmonella typhimurium* M525 :: TetC, (Fragment C of tetanus toxin, to act as an antigen for subsequent antibody quantification), and followed for 28 days. On day 14 post-infection (pi), four mutant and four wt mice were sacrificed by cervical dislocation and organs (spleen, liver and caecum) removed. A small piece of spleen and liver was fixed in 4% formalin and then later processed to paraffin blocks as an infected tissue biobank. The rest of the organs were weighed then homogenized, serially diluted and plated

to determine viable bacterial load. At day 28 pi, the remaining four mice were culled by cardiac puncture under terminal anesthesia and organs removed and processed, as above. The blood was allowed to clot, then centrifuged, serum collected and used to detect TetC antigen specific antibodies by enzyme-linked immunosorbent assay (ELISA). Mice were weighed and monitored daily for signs of pathophysiology.

Influenza challenge

Mutant and wt mice (5-21 weeks of age) were lightly anesthetised and intranasally inoculated with 171 or 227 p.f.u. of A/X-31 (H3N2) influenza in 50µl of sterile PBS. Mouse weight was recorded daily and the percent reduction was calculated from their weight on day 0. Mice were sacrificed by cervical dislocation on day 10 pi, and the area under the curve from day 0 to 9 pi was calculated. Mice exceeding 25% total weight loss were culled in accordance with UK Home Office guidelines.

Trichuris muris challenge

The Edinburgh (E) strain of *Trichuris muris* was used in all experiments. Female mice (6–12 weeks old) were orally infected with 400 embryonated eggs. Mice were culled by cervical dislocation at day 32 pi, blood was collected by cardiac puncture for serum recovery, and caecum/proximal colon was dissected to inspect for worm presence by stereomicroscope. Levels of parasite-specific serum IgG1 and IgG2a Ab were by ELISA: briefly, ELISA plates were coated with *T. muris* excretory/secretory (E/S) antigen at 5µg/ml. Serum was diluted 1/40, and parasite-specific IgG1, IgG2a and IgE detected with biotinylated anti-mouse IgG1 (Biorad), biotinylated anti-mouse IgG2a (BD PharMingen), and anti-mouse IgE (Biolegend), respectively. To generate *T. muris* E/S antigen, live adult worms were incubated at 37°C for 24h in RPMI-1640 medium (Gibco, UK) supplemented with 500 U/ml penicillin, 500µg/ml streptomycin and 2mM L-glutamine (all Gibco, UK). Supernatants were removed, centrifuged at 2000g for 15 minutes, filtered through a 0.22µm filter (Millipore, UK), concentrated using a 10kD molecular weight cut off Centriprep concentrator (Amicon, UK) and dialysed against PBS over a 24h period. The supernatant was subsequently filtered again and protein concentration determined before use.

Statistical analysis

Sample sizes for each experimental group are included in the figure legends. Measures were taken from distinct samples in almost all experiments. Exceptions are body weight, where the weight of the same animal was recorded repeatedly during the course of the experiment and the CTL assay, in which T cells from the same culture were used for different effector : target ratios. Statistical tests are mentioned in the figure legends, more complex procedures like the reference range are explained below. All tests used were two-sided. Co-variates were included in the analysis indirectly, by dividing animals into sex-specific groups or matching ko

and wt by assay date/weight/age (MMR analysis described below) and in the analysis presented in figures 7 E and F where covariates tested are described in the text. Experimental batch effects were minimised by the experimental design, see above. Reference-range tests which require no assumptions were used for most assays. Adjustments for multiple comparisons were not made unless stated in test description, as individual comparisons were not independent (e.g. percentages for different cell types determined by flow cytometry are often nested and dependent on each other). Low false positive rates were instead ensured by using conservative reference range cut-offs and monitoring false positive rates by simulation (**Fig S3**). A description of statistical parameters is included into the figure legends. Effect sizes are given when fold change between sexes was analysed.

Hit-calling for BM, spleen and MLN flow cytometry phenotypes, ANA and DSS colitis was guided by robust baseline measurements and rolling assessments of immunophenotypic variation in successive windows, each containing $\geq$70 age-matched and sex-matched, co-located, wt controls. In this way, animals from one strain were compared against their sex and test-day specific reference range (modified reference range, MRR). For data from blood and ear epidermis screens, the reference range (RR) was sex-specific, but included data from the whole duration of the screen (*43*).

In flow and DSS screens, if more than 60% of animals from a strain were beyond 97.5 percentile of MRR/RR or below 2.5 percentile of MMR/RR, the strain was considered a significant phenotype. Fisher's exact test was used for categorical ANA data.

For responses to infection, hit-calling relied on concurrent controls.
ANOVA was used for influenza data; a Mann-Whitney-U test for *Salmonella* data. An overview of all statistical methods is provided (**Supplementary Table 4**). All significant calls were manually reviewed by biological experts. Analysis was carried out using R (*47*).

Coefficient of variation (CV) was estimated as a ratio of the standard deviation of the wt population to its mean (for both sexes together, unless indicated otherwise). Note that since a data-set is expressed as frequency of parent, it is bound and CV estimates are less accurate close to the boundary.

Sexual dimorphism
Significance of sex as a source of variation in wt animals was tested in a mixed model (sex as explanatory variable, assay date as a random effect) by examining the contribution of sex to the model and whether the variance was homogeneous between sexes[59]. The effect of multiple testing was managed with Bonferroni correction to control the family-wise error rate to 5%. For Principal Component Analysis and Linear discriminant analysis (LDA), only wt samples with a complete set of flow parameters were used. Data was scaled. Accuracy of classification by sex in LDA was checked with leave-one-out cross-validation.

Estimation of false positive rates

A mutant mouse line was mimicked by randomly selecting N wt animals (N depending on the screen) and assessed whether it would be called a hit using the RR approach. To reflect the data structure and address the potentially confounding batch effect of test days, the number of experimental days from which animals were drawn and their sex was set according to the distributions observed across all tested mutant lines. For example, in the lab, bone marrow was collected on five different days in 36% of mouse strains; in 38% on four different dates; in 11% from three different days and so on. When strains were tested on four assay days, in 78% of cases females were tested on two days and so on. The same data structure was imposed on the draws for the false positive rates. Thereupon, the same rubric used for calling hits from real data was applied, except that the expert data review step (see above) was replaced by filtering out samples from the days when the median of wt animals and non-significant mutant strain samples was further than two median absolute deviations (MADs) from the overall median in wt animals. 10,000 draws were performed for each parameter to determine the rate at which false positives would occur.

Correlation analysis

Pearson correlations between parameters in the flow cytometry screens and the ear epidermis screen as well as between the flow cytometry screens and non-immune screens were identified in wt mice for pairwise complete observations, accumulated throughout whole duration of the experiment. Correlations with parent and sister populations were excluded from the dataset. Correlations with $R>0.33$ and $p<0.0001$ were considered significant.

Comparison of correlations between male and female mice

R values of all significant correlations were compared with a t-test after Fisher z-transformation. Difference in dependence between parameters between sexes (slope of regression line) was tested by fitting a linear regression model to correlated parameters and assessing significance of interaction between sex and predictor variable. P-values were adjusted for multiple testing with Bonferroni correction to control the family wise error rate to 5%.

Immunological structure analysis

Starting from parameters that were affected in a mutant strain, a list was compiled of other parameters with which the affected parameter was ordinarily correlated. The wt data were then used to predict a value for the correlated parameter in the mutant strain by sex-specific linear regression. If ≥60% of mice for a given mutant strain had predicted values outside the 95% confidence interval based on the wt distribution, the mutant line was defined as breaking this specific parameter correlation. Note that a single perturbed parameter could contribute more than one correlation to the dataset. For the purpose of this analysis, it was assumed

that all correlations were equally likely to be broken. To assess if breaking of correlations was correlated with other characteristics, such as a non-immune phenotype or a challenge phenotype, a multivariate Probit regression analysis was undertaken. The same analysis was also used to control for unequal numbers of correlations per gene, allowing for dependencies of correlations within a gene by cluster-robust standard errors and for separate contributions of all characteristics tested ($p<0.001$ for non-immune controlling for challenge, $p<0.001$ for challenge controlling for non-immune).

GnomAD, OMIM and GWAS analyses

If homo-and heterozygotes were analysed from the same strain, only homozygotes were included in this analysis. Human orthologues were based on JAX definition (http://www.informatics.jax.org, accessed 05.05.2016) and only 1:1 human-mouse orthologues were used. GnomAD scores were extracted from release 2 (Hail Table (gs://gnomad-public/release/2.1/ht/constraint/constraint.ht). Statistical significance of enrichment was assessed by Fisher's exact test, using the cut-off of 0.9 used by Lek et al[18].

OMIM annotations were obtained on 31 May 2017, with immune-related OMIM-listed genes considered as those implicated in phenotypes of immunodeficiency, recurrent infections, autoimmunity.

GWAS associations were obtained from the full NHGRI-EBI GWAS catalog database 78 on September 10, 2017 (file gwas_catalog_v1.0.1-associations_e89_r2017-07-31.tsv). In GWAS annotation, "immune-related" genes were considred as those mapping to susceptibility to autoimmune disease (systemic lupus erythematosus, psoriasis, rheumatoid arthritis, Sjögren syndrome, primary biliary cholangitis, ulcerative colitis, inflammatory bowel disease, Crohn's disease, multiple sclerosis, type 1 diabetes, Graves' disease, late-onset myasthenia gravis); immune response to virus (measured by secreted TNF-alpha); and functional units of gut microbiota.

Data Availability

The datasets generated and analysed during the current study are available on www.immunophenotype.org and www.mousephenotype.org. Raw FCS flowcytometric files are available from FlowRepository (flowrepository.org). Image files are available from the corresponding author upon request.

The following figures have associated raw data which is available from the above-mentioned sources: 1B-D, 2A-C, 4B-C, 5B-E, 6A-D, 7B-F, S1B-H, S2, S3A-D.
Code and preprocessed data for candidate hit calling for flow cytometry, immune epidermis and DSS assays is <https://github.com/AnnaLorenc/3i_heatmapping>.

All mouse lines analysed in this work are available from repositories linked to the International Mouse Phentoyping Consortium (www.mousephenotype.org) or from WTSI (email mouseinterest@sanger.ac.uk). Cell lines are available upon request.

The PhenStat R package used for Influenza analysis is available on Bioconductor (www.bioconductor.org). The ImageJ macro and the Python code used to score ANA positivity, the Definiens Developer code to assess the ear epidermis images and the R code used to assess the false positive rate are available on request.

Supplementary Tables 1-5

Supplementary Table 1

Markers and fluorochromes used to identify immune cell populations by flow cytometry

Laser	LP Filter	BP filter	Fluoro-chrome	SPL/MLN T/NK cells	SPL/MLN B cells	SPL/MLNM yeloid cells	SPL Myeloid / B cells	Bone marrow
405	-	450/50	BV421	KLRG1	CD23	CD5/19/161	CD23	IgM
405	505	525/50	BV510	CD5	CD5	CD11b	CD11b	CD11b
405	595	610/20	Qdot-605	CD45	CD45	CD45		CD45
405	630	670/30	BV650	CD161	CD138	CD317	CD161	CD138
405	750	780/60	BV786	CD4	IgM	CD11c	CD11c	CD3
488	505	530/30	FITC	CD44	CD21/35	MHC II	MHC II	IgD
488	685	710/50	PerCP-Cy5.5	CD62L	IgD	F4/80		CD43
561	570	585/15	PE	GITR	IgG1	CD103	CD21/35	BP-1
561	750	780/60	PE-Cy7	TCRδ	CD95	CD86	CD19	B220
640	-	670/14	APC	CD25		Ly6G	CD5	CD24
			AF647		GL7			
640	690	730/45	AF700	CD8α	B220	Ly6C	Ly6C	Gr1
640	750	780/60	NIR	Live/Dead	Live/Dead	Live/Dead	Live/Dead	Live/Dead

Laser	LP Filter	BP filter	Fluoro-chrome	PBL T/NK cells	PBL Myeloid/ B cells
405	-	450/50	BV421	CD161	
			V450		Ly6G
405	505	525/50	BV510	CD4	IgD
488	505	530/30	FITC	CD44	Ly6B
488	550	575/26	PE	CD25	MHC II
488	600	610/20	PE-CF594	CD62L	CD19
488	685	695/40	PerCP-Cy5.5	TCRβ	Ly6C
488	755	780/60	PE-Cy7	Klrg1	CD11b
633	-	660/20	APC	TCRδ	CD115
633	710	730/45	AF700	CD45	CD45
633	755	780/60	APC-H7	CD8α	

Supplementary Table 2: Parameters of flow cytometry and ear epidermis assays

Parameter	Cell markers
Spleen and mesenteric lymph node	
Total γδ T cells	TCRδ+
CD5+ γδ T cells	TCRδ+ CD5+
Effector γδ T cells	TCRδ+ CD62L- CD44+
Resting γδ T cells	TCRδ+ CD562L+
KLRG1+ γδ T cells	TCRδ+ KLRG1+
Total αβ T cells	TCRδ- CD5+ CD4+ or CD8+
Total CD4+ T cells	TCRδ- CD5+ CD4+
CD4+ T helper cells	TCRδ- CD5+ CD4+ CD25- GITR-
Effector CD4+ T helper cells	TCRδ- CD5+ CD4+ CD25- GITR- CD62L- CD44+
Resting CD4+ T helper cells	TCRδ- CD5+ CD4+ CD25- GITR- CD62L+
KLRG1+ CD4+ T helper cells	TCRδ- CD5+ CD4+ CD25- GITR- KLRG1+
Total Treg cells	TCRδ- CD5+ CD4+ CD25+ GITR+
Effector Treg cells	TCRδ- CD5+ CD4+ CD25+ GITR+ CD62L- CD44+
Resting Treg cells	TCRδ- CD5+ CD4+ CD25+ GITR+ CD62L+
KLRG1+ Treg cells	TCRδ- CD5+ CD4+ CD25+ GITR+ KLRG1+
Total CD8+ T cells	TCRδ- CD5+ CD8+
Total CD8+ T cells	TCRδ- CD5+ CD8+ CD25- GITR-
Effector CD8+ T cells	TCRδ- CD5+ CD8+ CD25- GITR- CD62L- CD44+
Resting CD8+ T cells	TCRδ- CD5+ CD8+ CD25- GITR- CD62L+ CD44+
Naive CD8+ T cells	TCRδ- CD5+ CD8+ CD25- GITR- CD62L+ CD44-
KLRG1+ CD8+ T cells	TCRδ- CD5+ CD8+ CD25- GITR- KLRG1+
Total NKT cells	TCRδ- CD5+ CD161+
Total CD4- NKT cells	TCRδ- CD5+ CD161+ CD4-
Effector CD4- NKT cells	TCRδ- CD5+ CD161+ CD4- CD62L-
Resting CD4- NKT cells	TCRδ- CD5+ CD161+ CD4- CD62L+
KLRG1+ CD4- NKT cells	TCRδ- CD5+ CD161+ CD4- KLRG1+
Total CD4+ NKT cells	TCRδ- CD5+ CD161+ CD4+
Effector CD4+ NKT cells	TCRδ- CD5+ CD161+ CD4+ CD62L-
Resting CD4+ NKT cells	TCRδ- CD5+ CD161+ CD4+ CD62L+
KLRG1+ CD4+ NKT cells	TCRδ- CD5+ CD161+ CD4+ KLRG1+
Total NK cells	TCRδ- CD5- CD161+
Effector NK cells	TCRδ- CD5- CD161+ CD62L-
Resting NK cells	TCRδ- CD5- CD161+ CD62L+
KLRG1+ NK cells	TCRδ- CD5- CD161+ KLRG1+
Plasma cells	CD138+
B1a cells	CD138- B220+ CD5+
B2 cells	CD138- B220+ CD5-
Follicular B cells	CD138- B220+ CD5- GL7- CD95- CD21/35^{int} IgM^{int}
Memory B cells	CD138- B220+ CD5- GL7- CD95- IgG+
Macrophages	F4/80+ CD11b^{int}
Granulocytes	F4/80- Ly6G^{high} CD11b+
Eosinophils	F4/80- Ly6G^{int} CD11b+ SSC^{high}

Monocytes	F4/80- Ly6G- Ly6C^{high} CD11b+
Plasmacytoid DC	F4/80- Ly6G- Ly6C$^{low/int}$ CD317+
Conventional DC	F4/80- Ly6G- Ly6C$^{low/int}$ CD317- CD11c+ MHCII+
Conventional CD11b^{high} DC	F4/80- Ly6G- Ly6C$^{low/int}$ CD317- CD11c+ MHCII+ CD11b^{high} CD86^{low}
Conventional CD11b^{low} DC	F4/80- Ly6G- Ly6C$^{low/int}$ CD317- CD11c+ MHCII+ CD11b^{low} CD86^{high}
CD103+ conventional CD11b^{low} DC	F4/80- Ly6G- Ly6C$^{low/int}$ CD317- CD11c+ MHCII+ CD11b^{low} CD86^{high} CD103+
Spleen only	
Immature NK cells	Ly6G- CD161+ CD5- CD11b- Ly6C-
Ly6C+ immature NK cells	Ly6G- CD161+ CD5- CD11b- Ly6C+
Mature NK cells	Ly6G- CD161+ CD5- CD11b+ Ly6C-
Ly6C+ mature NK cells	Ly6G- CD161+ CD5- CD11b+ Ly6C+
Germinal centre B cells	CD138- B220+ CD5- GL7+ CD95+
Early germinal centre B cells	CD138- B220+ CD5- GL7+ CD95+ IgM+ IgG-
Late germinal centre B cells	CD138- B220+ CD5- GL7+ CD95+ IgM- IgG+
Marginal zone precursor B cells	CD138- B220+ CD5- GL7- CD95- CD21/35+ CD23-
Marginal zone B cells	CD138- B220+ CD5- GL7- CD95- CD21/35+ CD23+
Transitional 1 B cells	CD138- B220+ CD5- GL7- CD95- CD21/35- CD23-
Transitional 2 B cells	CD138- B220+ CD5- GL7- CD95- CD21/35- CD23+
Blood	
Total T cells	TCRβ+ or TCRδ+
Total αβ T cells	TCRβ+
Total CD4+ T cells	TCRβ+ CD4+
Effector CD4+ T cells	TCRβ+ CD4+ CD62L- CD44+
Klrg1+ CD4+ T cells	TCRβ+ CD4+ Klrg1+
Total Treg cells	TCRβ+ CD4+ CD25+
Total CD8+ T cells	TCRβ+ CD8+
Effector CD8+ T cells	TCRβ+ CD8+ CD62L- CD44+
Klrg1+ CD8+ T cells	TCRβ+ CD8+ KLRG1+
Total γδ T cells	TCRδ+
Total NKT cells	TCRβ+ CD161+
Total NK cells	TCRβ- CD161+
KLRG1+ NK cells	TCRβ- CD161+ KLRG1+
Total B cells	CD19+
IgD+ mature B cells	CD19+ IgD+
Monocytes	CD19- Ly6G- CD11b+
Ly6C+ monocytes	CD19- Ly6G- CD11b+ Ly6C+
Ly6C- monocytes	CD19- Ly6G- CD11b+ Ly6C-
Neutrophils	CD19- Ly6G+ Ly6B+
Eosinophils	CD19- Ly6B- Ly6G- SSC^{Hi} CD11b+

Bone marrow	
Granulocytes	GR+ CD43+
T cells	GR- CD3+
Plasma cells	GR- CD3- CD138+
Myeloid cells	GR- CD3- CD138- CD11b+
Total B cell precursors	GR- CD3- CD138- B220+
Pre-pro B cells (Hardy fraction A)	GR- CD3- CD138- B220+ CD43+ BP1- CD24-
Pro-B cells (Hardy fraction B)	GR- CD3- CD138- B220+ CD43+ BP1- CD24+
Pro-B cells (Hardy fraction C)	GR- CD3- CD138- B220+ CD43+ BP1+ CD24+
Pre-B cells (Hardy fraction D)	GR- CD3- CD138- B220+ CD43- IgD- IgM-
Immature B cells (Hardy fraction E)	GR- CD3- CD138- B220+ CD43- IgD- IgM+
Mature B cells (Hardy fraction F)	GR- CD3- CD138- B220+ CD43- IgD+ IgM+
Ear epidermis	
DETC coverage	
Count of DETC Vγ5+	
Count of atypical CD45+ cells	
Count of DETC Vγ5+ contacting LC	
Count of DETC Vγ5+ not contacting LC	
Count of LC	
Average volume of DETC Vγ5+	
Average volume of atypical CD45+ cells	
Average volume of DETC Vγ5+ contacting LC	
Average volume of DETC Vγ5+ not contacting LC	
Average volume of LC	
Average roundness of DETC Vγ5+	
Average roundness of atypical CD45+ cells	
Average roundness of DETC Vγ5+ contacting LC	
Average roundness of DETC Vγ5+ not contacting LC	
Average roundness of LC	
Average number of branches on DETC Vγ5+	
Average number of branches on DETC Vγ5+ contacting LC	
Average number of branches on DETC Vγ5+ not contacting LC	
Average number of branches on LC	
Average branch length of on DETC Vγ5+	
Average branch length of on DETC Vγ5+ contacting LC	
Average branch length of on DETC Vγ5+ not contacting LC	

Supplementary Table 3: Summary of statistical procedures per assay and readout

Assay	Readouts	Statistical test	Choice of controls	Number of successfully phenotyped strains/mice
Ear epidermis (2F, 2M)	Number of cells and morphological parameters recorded by 3D confocal analysis and analysed by an automated script using Definiens developer software	Mutant samples were considered phenodeviant when falling into the lower or upper 2.5 percentiles of the wild type distribution of their respective sex. A mutant line was considered phenodeviant when ≥60% of samples across sexes (3/4 or 3/3) fell outside their respective reference range.	all wt data, sex-matched	499 strains 2066 ko mice 728 wt mice
Cytotoxic T cell lysis (2F, 2M)	Percentage of target cell lysis recorded relative to a positive control (detergent)			265 strains 1130 ko mice 566 wt mice
Blood (7F, 7M)	Frequencies/cell numbers of cell populations recorded by flow cytometry. Frequencies are reported as a percentage of parental population, and absolute numbers are calculated using	As for ear epidermis, but owing to the larger sample size, phenodeviants were also identified within each sex separately.	all wt data, sex-matched	534 strains 7010 ko mice 2652 wt mice

	white blood cell counts from haematology data.			
Spleen/ MLN/BM (3F, 3M)	Frequencies of cell populations recorded by flow cytometry. Frequencies are reported as a percentage of parental population or as percentage of $CD45^+$, live, single cells.	As for ear epidermis. A mutant line was considered phenodeviant when ≥60% of samples across sexes (6/6, 5/6, 4/6, 3/5, 3/4 or 3/3) fell outside their respective reference range.	70 sex matched wt samples that were closest in time to the mutant sample assessed.	Spleen: 520 strains 3169 ko mice 947 wt mice MLN: 511 strains 2986 ko mice 858 wt mice Bone marrow: 482 strains 2622 ko mice 795 wt mice
DSS histology and weight data (2F, 2M or 4F)	A) Histological scoring of gut sections B) Percentage of reduction in body weight compared to the start of the experiment.	As for ear epidermis	sex-matched wt data, 70 individuals closest in starting weight (A) or age (B)	492 strains 2001 ko mice 868 wt mice
Salmonella bacterial burden and serum antibodies (4F, 4M)	A) Colony forming units (CFU) of bacteria cultured on LB agar isolated from spleen and liver homogenates B) Titers of antigen-specific antibodies in serum measured by ELISA	Hits were identified by a Mann-Whitney-U test with a p-value cut-off of 0.05 in comparison to concurrent wt controls. The analysis combined data from male and female mice. Significant lines were retested with a second cohort. A final call was made on the combined data from both experiments.	concurrent wt controls	518 strains 4133 ko mice 1723 wt mice

Influenza weight data: (3F, 3M)	Percentage of reduction in body weight compared to the start of the experiment.	Hits were identified by fitting a robust mixed model (corresponding to two-way Anova) with a p-value cut-off of 0.0001, in comparison to concurrent wt controls, taking into account sex and genotype, using the R package Phenstat[60]. Residuals were assumed to be normally distributed. Calls were made when a genotype has a significant main effect on weight loss.	concurrent wt controls	490 strains 3033 ko mice 1054 wt mice
ANA (3F, 3M)	Scores for ANA positivity assessed by microscopy and analysed using a Python script. Scores between 0 and 1.5 were considered negative; scores of 2- 4 were considered positive.	Hits were identified by Fisher's exact test with a p-value cut-off of 0.01, comparing the frequency of positive samples in mutant and wt	wt animals from the contemporaneous 3 months period	520 strains 3286 ko mice 1123 wt mice
DSS and influenza survival data	Number of mice having to be culled because of excessive weight loss before the end of the experiment	Hits were identified by Fisher's exact test with a p-value cut-off of 0.01, comparing the frequency of mice with above threshold weight loss in a mutant strain with wt population, combining data from both sexes.	all wt animals	as for DSS and influenza above

*some genes were tested in several alleles (i.e. with more than one strain).

Supplementary Table 4: Alleles of knockout lines included in the study

1700001C02Rik$^{tm1a(EUCOMM)Wtsi}$	*Dpy30*$^{tm1a(KOMP)Wtsi}$	*Pclaf*$^{tm1a\ (EUCOMM)Wtsi}$
1700007K13Rik$^{tm2b(EUCOMM)Wtsi}$	*Duoxa2*$^{tm1b(KOMP)Wtsi}$	*Pdcd2*$^{tm1b(EUCOMM)Wtsi}$
1700011A15Rik$^{tm1a(KOMP)Wtsi}$	*Dusp5*$^{tm1a(KOMP)Wtsi}$	*Pdia4*$^{tm1b\ (EUCOMM)Wtsi}$
1700024P04Rik$^{tm1b(EUCOMM)Wtsi}$	*Dynlrb2*$^{tm1a(KOMP)Wtsi}$	*Pdk3*$^{tm2a(KOMP)Wtsi}$
1700029H14Rik$^{tm2b(KOMP)Wtsi}$	*MIR342* $^{Brd(tm1)}$	*Pdzk1*$^{tm2b(EUCOMM)Wtsi}$
1700034J05Rik$^{tm1a(KOMP)Wtsi}$	*Mir210*$^{(tm1)Brd}$	*Pepd*$^{tm1a(KOMP)Wtsi}$
1700067K01Rik$^{tm2a(KOMP)Wtsi}$	*Mir211*$^{(tm1)Brd}$	*Pgap2*$^{tm1b(EUCOMM)Wtsi}$
1700112E06Rik$^{tm1e(EUCOMM)Wtsi}$	*Eci3*$^{tm1b(EUCOMM)Wtsi}$	*Pigf*$^{tm1a(KOMP)Wtsi}$
1700123O20Rik$^{tm1a(EUCOMM)Wtsi}$	*Eif3h*$^{tm1a(EUCOMM)Hmgu}$	*Pigl*$^{tm1b(KOMP)Wtsi}$
2010300C02Rik$^{tm1b(KOMP)Wtsi}$	*Elac2*$^{tm1b(EUCOMM)Wtsi}$	*Pitrm1*$^{tm1a(KOMP)Wtsi}$
2610034B18Rik$^{tm1b(EUCOMM)Wtsi}$	*Ell2*$^{tm1b(EUCOMM)Wtsi}$	*Pitx1*$^{em1(IMPC)Wtsi}$
3300002A11Rik$^{tm1a(KOMP)Wtsi}$	*Enc1*$^{tm1a(EUCOMM)Wtsi}$	*Pla2g6*$^{tm1a(EUCOMM)Wtsi}$
3830406C13Rik$^{tm1b(KOMP)Wtsi}$	*Enthd2*$^{tm1b(KOMP)Wtsi}$	*Pld3*$^{tm1e(EUCOMM)Wtsi}$
4930404H24Rik$^{tm1a(KOMP)Wtsi}$	*Erlin2*$^{tm1a(EUCOMM)Wtsi}$	*Plet1*$^{em1(IMPC)Wtsi}$
4930590J08Rik$^{tm1a(EUCOMM)Wtsi}$	*Evi5*$^{tm1a(KOMP)Wtsi}$	*Plscr2*$^{tm1b(KOMP)Wtsi}$
4931429L15Rik$^{tm1a(EUCOMM)Wtsi}$	*Exoc3l2*$^{tm1b(KOMP)Wtsi}$	*Plxnb3*$^{tm1a(KOMP)Wtsi}$
4932431P20Rik$^{em1(IMPC)Wtsi}$	*Exosc9*$^{tm1b(EUCOMM)Wtsi}$	*Polb*$^{tm1a(KOMP)Wtsi}$
4933402N03Rik$^{tm2a(KOMP)Wtsi}$	*Fads3*$^{tm1b(EUCOMM)Wtsi}$	*Pold3*$^{tm1b(EUCOMM)Wtsi}$
4933434E20Rik$^{tm1a(EUCOMM)Wtsi}$	*Fam122c*$^{tm1b(EUCOMM)Wtsi}$	*Polr3f*$^{tm1a(EUCOMM)Wtsi}$
5730559C18Rik$^{tm2a(EUCOMM)Wtsi}$	*Fam160a1*$^{tm1b(EUCOMM)Wtsi}$	*Polr3g*$^{tm1a(EUCOMM)Wtsi}$
9330182L06Rik$^{tm1a(KOMP)Wtsi}$	*Fam163a*$^{tm2b(KOMP)Wtsi}$	*Ppil3*$^{tm1b(EUCOMM)Wtsi}$
A430005L14Rik$^{tm1a(KOMP)Wtsi}$	*Fam212b*$^{tm1a(KOMP)Wtsi}$	*Prame*$^{tm1a(KOMP)Wtsi}$
A430078G23Rik$^{tm1a(KOMP)Wtsi}$	*Fam47e*$^{tm1a(EUCOMM)Wtsi}$	*Prkab1*$^{tm1b(KOMP)Wtsi}$
A730017C20Rik$^{tm1b(KOMP)Wtsi}$	*Fam69a*$^{tm1a(EUCOMM)Wtsi}$	*Prrc2b*$^{tm1a(EUCOMM)Wtsi}$
Abhd14a$^{tm2a(EUCOMM)Wtsi}$	*Fam71b*$^{tm1a(KOMP)Wtsi}$	*Prrg2*$^{tm1b(EUCOMM)Wtsi}$
Abhd17a$^{tm1a(KOMP)Wtsi}$	*Fam92a*$^{tm1b(KOMP)Wtsi}$	*Prrt2*$^{tm1a(KOMP)Wtsi}$
Acbd5$^{tm1b(EUCOMM)Wtsi}$	*Fbf1*$^{tm1a(EUCOMM)Wtsi}$	*Prss52*$^{tm2a(KOMP)Wtsi}$
Acer1$^{tm1a(EUCOMM)Wtsi}$	*Fbxo33*$^{tm1b(EUCOMM)Wtsi}$	*Psph*$^{tm1a(EUCOMM)Hmgu}$
Actl10$^{tm1a(EUCOMM)Wtsi}$	*Fbxw26*$^{tm1b(KOMP)Wtsi}$	*Pth1r*$^{tm1a(EUCOMM)Hmgu}$

Adal$^{tm1a(EUCOMM)Wtsi}$	*Fdft1*$^{tm1a(KOMP)Wtsi}$	*Pth*$^{tm1a(EUCOMM)Wtsi}$
Adamts19$^{tm4a(EUCOMM)Wtsi}$	*Fkbp3*$^{tm2a(EUCOMM)Wtsi}$	*Ptprd*$^{tm2a(KOMP)Wtsi}$
Adamts3$^{tm1b(KOMP)Wtsi}$	*Fnip2*$^{tm1a(KOMP)Wtsi}$	*Pwp1*$^{tm1a(EUCOMM)Wtsi}$
Adap1$^{tm1a(EUCOMM)Wtsi}$	*Fryl*$^{tm1b(KOMP)Wtsi}$	*Pycr2*$^{tm1a(EUCOMM)Wtsi}$
Adcy2$^{tm1a(KOMP)Wtsi}$	*Fxyd3*$^{tm1a(KOMP)Wtsi}$	*Rab17*$^{tm1a(KOMP)Wtsi}$
Adcy9$^{tm1b(EUCOMM)Wtsi}$	*Fzd6*$^{tm2a(EUCOMM)Wtsi}$	*Rab21*$^{tm1b(KOMP)Wtsi}$
Adgrd1$^{tm1b(EUCOMM)Wtsi}$	*Galnt18*$^{tm1b(KOMP)Wtsi}$	*Raph1*$^{tm1b(EUCOMM)Wtsi}$
Adpgk$^{tm2a(EUCOMM)Wtsi}$	*Galntl5*$^{tm1b(KOMP)Wtsi}$	*Rbak*$^{tm1b(KOMP)Wtsi}$
Agap1$^{tm1a(EUCOMM)Wtsi}$	*Gbp5*$^{em1(IMPC)Wtsi}$	*Rbm14*$^{tm1a(KOMP)Wtsi}$
Aicda$^{tm1b(EUCOMM)Hmgu}$	*Gda*$^{tm1a(KOMP)Wtsi}$	*Rbm33*$^{tm1b(EUCOMM)Wtsi}$
Aldh1b1$^{tm2a(EUCOMM)Wtsi}$	*Gdpd2*$^{tm1a(KOMP)Wtsi}$	*Rbm47*$^{tm1a(EUCOMM)Wtsi}$
Aldh3b1$^{tm1b(EUCOMM)Wtsi}$	*Gimap6*$^{tm1a(KOMP)Wtsi}$	*Rbmx*$^{tm2b(KOMP)Wtsi}$
Alox12e$^{tm1b(EUCOMM)Wtsi}$	*Glo1*$^{tm1a(KOMP)Wtsi}$	*Reg3d*$^{tm1b(EUCOMM)Wtsi}$
Alpk1$^{em1(IMPC)Wtsi}$	*Glyatl3*$^{em1(IMPC)Wtsi}$	*Repin1*$^{tm1a(EUCOMM)Wtsi}$
Amz2$^{tm1e(KOMP)Wtsi}$	*Gm12253*$^{tm1a(KOMP)Wtsi}$	*Rida*$^{tm1a(KOMP)Wtsi}$
Ankrd13d$^{tm1a(KOMP)Wtsi}$	*Gm13119*$^{tm2b(KOMP)Wtsi}$	*Rimbp2*$^{em1(IMPC)Wtsi}$
Ankrd6$^{tm1b(KOMP)Wtsi}$	*Gm13125*$^{tm1b(KOMP)Wtsi}$	*Rnasek*$^{tm1b(EUCOMM)Wtsi}$
Ankrd9$^{tm1(KOMP)Wtsi}$	*Gm16432*$^{tm1b(KOMP)Wtsi}$	*Rnf10*$^{tm1b(KOMP)Wtsi}$
Anks6$^{tm1b(KOMP)Wtsi}$	*Gm16515*$^{tm1b(EUCOMM)Wtsi}$	*Rnf125*$^{tm1a\ (EUCOMM)Wtsi}$
Ano10$^{tm1a(EUCOMM)Wtsi}$	*Gm5544*$^{tm1a(KOMP)Wtsi}$	*Rnf138*$^{tm1b(EUCOMM)Hmgu}$
Anxa9$^{tm1b(EUCOMM)Wtsi}$	*Gmds*$^{tm1a(KOMP)Wtsi}$	*Rnf157*$^{tm1b(EUCOMM)Wtsi}$
Ap2a2$^{em1(IMPC)Wtsi}$	*Gmnc*$^{tm1b(KOMP)Wtsi}$	*Rpia*$^{tm1a(KOMP)Wtsi}$
Ap4e1$^{tm1b(KOMP)Wtsi}$	*Gnb3*$^{tm1b(EUCOMM)Wtsi}$	*Rspo4*$^{tm1a(KOMP)Wtsi}$
Ap4m1$^{tm1b(EUCOMM)Wtsi}$	*Gpbp1l1*$^{tm1a(EUCOMM)Wtsi}$	*Rundc1*$^{tm1b(EUCOMM)Wtsi}$
Apip$^{tm1b(EUCOMM)Wtsi}$	*Gpr152*$^{tm1b(EUCOMM)Wtsi}$	*Rwdd1*$^{tm1b(KOMP)Wtsi}$
Apol9b$^{tm2a(KOMP)Wtsi}$	*Gpr35*$^{tm1b(EUCOMM)Hmgu}$	*Sap130*$^{tm1a(KOMP)Mbp}$
Apoo$^{tm1b(KOMP)Wtsi}$	*Grb7*$^{tm1b(EUCOMM)Wtsi}$	*Scaf11*$^{em1(IMPC)Wtsi}$
Arap2$^{tm2b(EUCOMM)Wtsi}$	*Grsf1*$^{tm1b(EUCOMM)Wtsi}$	*Selenow*$^{tm1b(EUCOMM)Wtsi}$
Arhgap17$^{tm1b(EUCOMM)Wtsi}$	*Gsdme*$^{tm1b(KOMP)Wtsi}$	*Sept10*$^{tm1a(KOMP)Wtsi}$
Arhgap22$^{tm1a(KOMP)Wtsi}$	*Gsto2*$^{tm2a(KOMP)Wtsi}$	*Serinc3*$^{tm1a(KOMP)Wtsi}$
Arhgef1$^{tm1a(EUCOMM)Wtsi}$	*Gt(ROSA)26Sor*^{ROSA26_Dre_C03}	*Setd5*$^{tm1a(EUCOMM)Wtsi}$

Armc7$^{tm1.1(KOMP)Wtsi}$	*Gtf2a1*$^{tm1a(KOMP)Wtsi}$	*Sfxn3*$^{tm1b(KOMP)Wtsi}$
Armh3$^{tm1a(EUCOMM)Wtsi}$	*Gtf2h2*$^{tm1a(EUCOMM)Wtsi}$	*Sgms1*$^{tm1a(EUCOMM)Wtsi}$
Arpc1b$^{tm1a(EUCOMM)Wtsi}$	*H13*$^{tm1b(KOMP)Wtsi}$	*Sgsm1*$^{tm1b(EUCOMM)Wtsi}$
Arrdc5$^{tm1b(EUCOMM)Wtsi}$	*Hao2*$^{em1(IMPC)Wtsi}$	*Sh3bgrl3*$^{tm2b(EUCOMM)Wtsi}$
Art4$^{tm1a(KOMP)Wtsi}$	*Hbs1l*$^{tm1a(KOMP)Wtsi}$	*Sh3bp4*$^{tm1a(EUCOMM)Wtsi}$
Atad3a$^{tm1a(KOMP)Wtsi}$	*Hecw2*$^{tm1a(EUCOMM)Wtsi}$	*Sh3pxd2a*$^{tm1b(EUCOMM)Wtsi}$
Atg16l2$^{tm1a(EUCOMM)Wtsi}$	*Hibadh*$^{tm1b(EUCOMM)Wtsi}$	*Sik3*$^{tm1a(EUCOMM)Hmgu}$
Atp11a$^{tm1a(KOMP)Wtsi}$	*Hmgxb3*$^{tm1a(EUCOMM)Wtsi}$	*Slamf9*$^{tm1b(EUCOMM)Wtsi}$
Atp5e$^{tm1b(EUCOMM)Wtsi}$	*Homez*$^{tm1e(KOMP)Wtsi}$	*Slc16a4*$^{tm2e(EUCOMM)Wtsi}$
Atp5f1$^{tm1b(EUCOMM)Wtsi}$	*Hpf1*$^{em1(IMPC)Wtsi}$	*Slc25a20*$^{tm1a(EUCOMM)Wtsi}$
Atp8b2$^{tm1a(KOMP)Wtsi}$	*Hrnr*$^{em1(IMPC)Wtsi}$	*Slc25a28*$^{tm1b(EUCOMM)Wtsi}$
Atxn10$^{tm1b(KOMP)Wtsi}$	*Ifi27*$^{tm1b(EUCOMM)Wtsi}$	*Slc38a2*$^{tm1a(KOMP)Wtsi}$
Atxn3$^{tm1a(KOMP)Wtsi}$	*Ifitm6*$^{tm1b(EUCOMM)Wtsi}$	*Slc5a7*$^{tm1a(KOMP)Wtsi}$
Bach2$^{tm1a(EUCOMM)Wtsi}$	*Ifnar1*$^{tm2a(EUCOMM)Wtsi}$	*Slc9a3r2*$^{tm2a(EUCOMM)Hmgu}$
Bai1$^{tm2a(EUCOMM)Wtsi}$	*Ifnlr1*$^{tm1a(EUCOMM)Wtsi}$	*Slitrk4*$^{tm1b(KOMP)Wtsi}$
Bap1$^{tm1a(EUCOMM)Hmgu}$	*Ift140*$^{tm1a(KOMP)Wtsi}$	*Slu7*$^{tm1a(KOMP)Wtsi}$
Barhl1$^{tm1(EGFP_CreERT2)Wtsi}$	*Il1r2*$^{tm1a(EUCOMM)Wtsi}$	*Slx4ip*$^{tm1a(EUCOMM)Wtsi}$
Bivm$^{tm1b(KOMP)Wtsi}$	*Il23r*$^{tm2a(EUCOMM)Wtsi}$	*Smg9*$^{tm1b(EUCOMM)Wtsi}$
Bnip2$^{tm1b(EUCOMM)Wtsi}$	*Il27*$^{tm1b(EUCOMM)Wtsi}$	*Smpd4*$^{tm2b(KOMP)Wtsi}$
Bpgm$^{tm1a(KOMP)Wtsi}$	*Irak1*$^{tm1b(EUCOMM)Hmgu}$	*Snx31*$^{tm1a(KOMP)Wtsi}$
Bpifb1$^{tm1e(KOMP)Wtsi}$	*Irf5*$^{tm1e(EUCOMM)Wtsi}$	*Snx8*$^{tm2a(EUCOMM)Hmgu}$
Bpifb5$^{tm2a(KOMP)Wtsi}$	*Izumo1r*$^{tm2a(KOMP)Wtsi}$	*Spata25*$^{tm1(KOMP)Wtsi}$
Brd2$^{em1(IMPC)Wtsi}$	*Josd1*$^{em1(IMPC)Wtsi}$	*Spink14*$^{tm1e(KOMP)Wtsi}$
Camkmt$^{tm1b(EUCOMM)Wtsi}$	*Kat2b*$^{em1(IMPC)Wtsi}$	*Sqle*$^{tm1a(EUCOMM)Wtsi}$
Camsap3$^{tm1a(EUCOMM)Wtsi}$	*Kcnh4*$^{tm1b(KOMP)Wtsi}$	*Srsf7*$^{tm1a(EUCOMM)Wtsi}$
Capn11$^{tm1b(EUCOMM)Wtsi}$	*Kera*$^{em1(IMPC)Wtsi}$	*Ssr2*$^{tm1b(EUCOMM)Wtsi}$
Capza2$^{tm1b(KOMP)Wtsi}$	*Kif13b*$^{tm1b(EUCOMM)Wtsi}$	*Stard8*$^{tm1b(EUCOMM)Wtsi}$
Card9$^{tm1a(EUCOMM)Hmgu}$	*Kif18b*$^{tm1a(EUCOMM)Wtsi}$	*Stau2*$^{tm1a(EUCOMM)Wtsi}$
Casc4$^{tm2b(EUCOMM)Wtsi}$	*Kif1bp*$^{tm1a(KOMP)Wtsi}$	*Stxbp4*$^{tm1a(EUCOMM)Wtsi}$
Catip$^{tm1b(KOMP)Wtsi}$	*Kif24*$^{tm1b(KOMP)Wtsi}$	*Sult1c1*$^{tm1b(KOMP)Wtsi}$
Cbr2$^{tm1b(EUCOMM)Hmgu}$	*Kif3b*$^{tm1b(EUCOMM)Wtsi}$	*Supt3*$^{tm1a(EUCOMM)Hmgu}$

Ccdc127$^{tm1b(EUCOMM)Wtsi}$	*Klc2*$^{tm1e(EUCOMM)Wtsi}$	*Supt5*$^{tm2a(KOMP)Wtsi}$
Ccdc159$^{tm1a(KOMP)Wtsi}$	*Klf17*$^{tm1b(KOMP)Wtsi}$	*Tbc1d22a*$^{tm1b(KOMP)Wtsi}$
Ccdc18$^{tm1a(EUCOMM)Wtsi}$	*Klhl18*$^{tm1a(KOMP)Wtsi}$	*Tceal5*$^{tm1b(KOMP)Wtsi}$
Ccdc69$^{tm1b(KOMP)Wtsi}$	*Klhl30*$^{tm1a(KOMP)Wtsi}$	*Tcf7l2*$^{tm1a(EUCOMM)Wtsi}$
Ccdc6$^{em1(IMPC)Wtsi}$	*Klk5*$^{tm2a(KOMP)Wtsi}$	*Tchp*$^{tm1a(EUCOMM)Wtsi}$
Cdkn2aipnl$^{tm1b(KOMP)Wtsi}$	*Klk6*$^{em1(IMPC)Wtsi}$	*Tcp11*$^{tm1a(EUCOMM)Wtsi}$
Celf4$^{tm1a(EUCOMM)Wtsi}$	*Klrb1a*$^{tm1a(KOMP)Wtsi}$	*Tctex1d2*$^{tm1e(EUCOMM)Wtsi}$
Cenpl$^{tm1b(EUCOMM)Wtsi}$	*Krt31*$^{tm1e(KOMP)Wtsi}$	*Tead3*$^{tm1a(EUCOMM)Wtsi}$
Cep250$^{tm1a(EUCOMM)Wtsi}$	*Krt7*$^{tm1b(KOMP)Wtsi}$	*Tent5c*$^{tm1b(KOMP)Wtsi}$
Cfap53$^{em1(IMPC)Wtsi}$	*Krt83*$^{tm1b(KOMP)Wtsi}$	*Tet1*$^{tm1a(KOMP)Wtsi}$
Cfap61$^{tm2a(EUCOMM)Wtsi}$	*L3mbtl2*$^{tm2a(EUCOMM)Wtsi}$	*Tex38*$^{tm1a(KOMP)Wtsi}$
Cgrrf1$^{tm1b(KOMP)Wtsi}$	*Lars*$^{tm1b(KOMP)Wtsi}$	*Tgfb1i1*$^{tm1b(KOMP)Wtsi}$
Chd9$^{tm1a(EUCOMM)Wtsi}$	*Lce1m*$^{tm1b(EUCOMM)Wtsi}$	*Tgm6*$^{tm1a(KOMP)Wtsi}$
Chil4$^{tm1b(EUCOMM)Hmgu}$	*Lce3c*$^{tm2a(EUCOMM)Wtsi}$	*Timeless*$^{tm1b(EUCOMM)Hmgu}$
Chmp6$^{tm1b(KOMP)Wtsi}$	*Ldhb*$^{tm1b(KOMP)Wtsi}$	*Timmdc1*$^{tm1b(EUCOMM)Wtsi}$
Chst11$^{tm1a(KOMP)Wtsi}$	*Ldlrad4*$^{tm1b(EUCOMM)Wtsi}$	*Tmc3*$^{tm2b(KOMP)Wtsi}$
Chtop$^{tm1a(EUCOMM)Wtsi}$	*Leo1*$^{tm1a(EUCOMM)Wtsi}$	*Tmem110*$^{tm2b(KOMP)Wtsi}$
Cir1$^{tm3a(KOMP)Wtsi}$	*Leprot*$^{tm2b(KOMP)Wtsi}$	*Tmem126a*$^{tm1a(EUCOMM)Wtsi}$
Clpp$^{tm1a(EUCOMM)Wtsi}$	*Lmna*^{G609G}	*Tmem127*$^{tm1(KOMP)Wtsi}$
Cmbl$^{tm1b(KOMP)Wtsi}$	*Lonrf3*$^{tm1b(KOMP)Wtsi}$	*Tmem18*$^{tm1b(EUCOMM)Wtsi}$
Cmtm5$^{tm1a(KOMP)Wtsi}$	*Lpxn*$^{tm1b(EUCOMM)Hmgu}$	*Tmem241*$^{tm1b(EUCOMM)Wtsi}$
Cnbd1$^{tm1b(EUCOMM)Wtsi}$	*Lrmp*$^{tm1b(EUCOMM)Wtsi}$	*Tmem254b*$^{tm1a(KOMP)Wtsi}$
Cnot4$^{tm1b(EUCOMM)Wtsi}$	*Lrrc23*$^{tm1a(EUCOMM)Wtsi}$	*Tmem30a*$^{tm1a(KOMP)Wtsi}$
Cog6$^{tm1a(EUCOMM)Wtsi}$	*Lrrc71*$^{tm1a(KOMP)Wtsi}$	*Tmem37*$^{tm1a(EUCOMM)Wtsi}$
Col24a1$^{tm1b(EUCOMM)Wtsi}$	*Lrrc8d*$^{tm1a(EUCOMM)Wtsi}$	*Tmem42*$^{tm1b(KOMP)Wtsi}$
Col4a3bp$^{tm1a(KOMP)Wtsi}$	*Lyplal1*$^{tm1a(KOMP)Wtsi}$	*Tomm20l*$^{tm1b(EUCOMM)Wtsi}$
Coro6$^{tm1e(EUCOMM)Wtsi}$	*Lyrm9*$^{tm1a(KOMP)Mbp}$	*Traf2*$^{tm1a(EUCOMM)Wtsi}$
Cpgi81$^{tm1.1(NCC)WCS*}$	*Macrod1*$^{em1(IMPC)Wtsi}$	*Traf6*$^{tm2a(EUCOMM)Wtsi}$
Cpsf3$^{tm1b(EUCOMM)Wtsi}$	*Mamstr*$^{tm1b(EUCOMM)Wtsi}$	*Trappc10*$^{tm1b(KOMP)Wtsi}$
Cpt2$^{tm1b(KOMP)Wtsi}$	*Mast2*$^{tm1a(KOMP)Wtsi}$	*Trappc9*$^{tm1a(EUCOMM)Wtsi}$
Crim1$^{em1(IMPC)Wtsi}$	*Mau2*$^{tm1b(KOMP)Wtsi}$	*Trem1*$^{tm1(KOMP)Vlcg}$

Crlf3$^{em1(IMPC)Wtsi}$	*Mbd1*$^{em1(IMPC)Wtsi}$	*Trim21*$^{em1(IMPC)Wtsi}$
Crls1$^{tm1a(EUCOMM)Wtsi}$	*Mbl2*$^{em1(IMPC)Wtsi}$	*Trim25*$^{tm2b(EUCOMM)Hmgu}$
Csmd1$^{em1(IMPC)Wtsi}$	*Mcf2l*$^{tm1a(EUCOMM)Hmgu}$	*Trim56*$^{tm1a(EUCOMM)Wtsi}$
Csnk1g3$^{tm1a(EUCOMM)Wtsi}$	*Med22*$^{tm1a(EUCOMM)Wtsi}$	*Trim65*$^{tm1b(KOMP)Wtsi}$
Ctr9$^{tm1b(EUCOMM)Wtsi}$	*Med23*$^{em1(IMPC)Wtsi}$	*Trmt2a*$^{tm2b(EUCOMM)Wtsi}$
Cttnbp2$^{tm1b(KOMP)Wtsi}$	*Medag*$^{tm2b(KOMP)Wtsi}$	*Trp53rkb*$^{tm1a(EUCOMM)Wtsi}$
Cutal$^{tm1a(EUCOMM)Wtsi}$	*Metrnl*$^{tm1b(KOMP)Wtsi}$	*Trub2*$^{tm2a(EUCOMM)Wtsi}$
Cxcr1$^{tm1a\ (EUCOMM)Wtsi}$	*Mettl24*$^{tm1a(KOMP)Wtsi}$	*Tuba3a*$^{tm1b(KOMP)Wtsi}$
Cxcr2$^{tm1a(EUCOMM)Wtsi}$	*Mgat4c*$^{tm1a(EUCOMM)Wtsi}$	*Tuft1*$^{tm1a(KOMP)Wtsi}$
Cyp2b13$^{tm1b(KOMP)Wtsi}$	*Mir32*$^{(tm1)Brd}$	*Ube2d1*$^{tm3e(EUCOMM)Wtsi}$
Cyp2r1$^{tm1b(EUCOMM)Wtsi}$	*Mir96*$^{tm2.2(IMPC)Wtsi}$	*Ubxn10*$^{tm1b(EUCOMM)Wtsi}$
D630023F18Rik$^{tm1b(KOMP)Wtsi}$	*Mospd1*$^{tm1a(KOMP)Wtsi}$	*Uevld*$^{tm1a(EUCOMM)Wtsi}$
D6Wsu163e$^{tm1b(EUCOMM)Wtsi}$	*Mpg*$^{tm1a(EUCOMM)Wtsi}$	*Umodl1*$^{tm1a(KOMP)Wtsi}$
D7Ertd443e$^{tm2a(KOMP)Wtsi}$	*Mrm1*$^{tm2a(EUCOMM)Wtsi}$	*Uri1*$^{tm1a(EUCOMM)Wtsi}$
D930028M14Rik$^{tm1a(EUCOMM)Wtsi}$	*Mroh4*$^{tm1b(KOMP)Wtsi}$	*Usp11*$^{tm1(KOMP)Wtsi}$
Dact3$^{tm1b(KOMP)Wtsi}$	*Mroh9*$^{tm1a(EUCOMM)Wtsi}$	*Usp20*$^{tm1a(EUCOMM)Hmgu}$
Daf2$^{tm1a(KOMP)Wtsi}$	*Mrps21*$^{tm1e(EUCOMM)Wtsi}$	*Usp30*$^{tm2b(EUCOMM)Hmgu}$
Dap$^{tm1a(KOMP)Mbp}$	*Mrps5*$^{tm1b(EUCOMM)Wtsi}$	*Usp37*$^{em1(IMPC)Wtsi}$
Dapk2$^{tm1b(EUCOMM)Wtsi}$	*Mybphl*$^{tm1b(KOMP)Wtsi}$	*Usp5*$^{tm1a(EUCOMM)Hmgu}$
Dbn1$^{tm1b(KOMP)Wtsi}$	*Myh7b*$^{tm1a(KOMP)Wtsi}$	*Vamp3*$^{tm2b(EUCOMM)Wtsi}$
Dcaf11$^{tm1a(KOMP)Wtsi}$	*Myo10*$^{tm2(KOMP)Wtsi}$	*Vps13a*$^{tm1b(EUCOMM)Wtsi}$
Dcbld2$^{tm1a(KOMP)Wtsi}$	*Myo9a*$^{tm1b(EUCOMM)Wtsi}$	*Vps33b*$^{tm1a(EUCOMM)Wtsi}$
Dcdc2b$^{tm1b(KOMP)Wtsi}$	*N6amt2*$^{tm1a(EUCOMM)Wtsi}$	*Vps51*$^{tm1a(KOMP)Wtsi}$
Dclk1$^{tm1a(EUCOMM)Wtsi}$	*Nacc2*$^{tm2b(EUCOMM)Wtsi}$	*Vps72*$^{tm1a(EUCOMM)Wtsi}$
Dcn$^{em1(IMPC)Wtsi}$	*Nadk2*$^{tm1b(EUCOMM)Wtsi}$	*Vwa3a*$^{tm1b(KOMP)Wtsi}$
Dctn4$^{em1(IMPC)Wtsi}$	*Nat10*$^{tm1a(KOMP)Wtsi}$	*Wac*$^{tm1b(EUCOMM)Wtsi}$
Ddah1$^{tm2a(EUCOMM)Wtsi}$	*Ncf2*$^{tm1a(EUCOMM)Wtsi}$	*Washc2*$^{tm2b(KOMP)Wtsi}$
Ddx42$^{tm1b(EUCOMM)Wtsi}$	*Ndufb8*$^{tm1a(EUCOMM)Wtsi}$	*Wdr89*$^{tm1a(KOMP)Wtsi}$
Ddx51$^{tm1a(KOMP)Wtsi}$	*Nebl*$^{tm1b(EUCOMM)Wtsi}$	*Wdtc1*$^{tm1a(KOMP)Wtsi}$
Defb14$^{tm1b(KOMP)Wtsi}$	*Nek3*$^{tm1b(EUCOMM)Wtsi}$	*Wnt16*$^{tm2b(EUCOMM)Wtsi}$
Defb22$^{tm1a(KOMP)Wtsi}$	*Nek9*$^{tm1a(EUCOMM)Wtsi}$	*Wrap53*$^{tm1b(EUCOMM)Wtsi}$

Defb30$^{tm2b(KOMP)Wtsi}$	*Nelfe*$^{tm1a(EUCOMM)Wtsi}$	*Xkrx*$^{tm1b(EUCOMM)Wtsi}$
Dennd1b$^{tm1a(EUCOMM)Hmgu}$	*Nfkbil1*$^{tm1a(KOMP)Wtsi}$	*Xpnpep1*$^{tm1a(KOMP)Wtsi}$
Dennd1c$^{tm1b(EUCOMM)Wtsi}$	*Nhlrc2*$^{tm1a(KOMP)Wtsi}$	*Xxylt1*$^{tm1a(EUCOMM)Hmgu}$
Dennd4c$^{tm1b(EUCOMM)Wtsi}$	*Nipsnap3a*$^{tm1b(KOMP)Wtsi}$	*Ydjc*$^{tm1(KOMP)Wtsi}$
Denr$^{tm1b(KOMP)Wtsi}$	*Nme4*$^{tm1a(EUCOMM)Wtsi}$	*Yipf7*$^{tm1e(KOMP)Wtsi}$
Dffb$^{em1(IMPC)Wtsi}$	*Nmrk1*$^{tm1a(KOMP)Wtsi}$	*Ypel4*$^{tm1a(EUCOMM)Wtsi}$
Dhodh$^{tm1b(EUCOMM)Wtsi}$	*Npat*$^{tm1b(EUCOMM)Wtsi}$	*Zbed5*$^{tm1b(EUCOMM)Wtsi}$
Dhps$^{tm2a(EUCOMM)Wtsi}$	*Nrbp1*$^{tm3b(EUCOMM)Wtsi}$	*Zfp182*$^{tm1b(KOMP)Wtsi}$
Dhx33$^{tm1b(KOMP)Wtsi}$	*Nrde2*$^{tm2a(KOMP)Wtsi}$	*Zfp239*$^{tm1b(KOMP)Wtsi}$
Dhx35$^{tm1b(EUCOMM)Wtsi}$	*Nudt12*$^{tm1a(KOMP)Wtsi}$	*Zfp266*$^{tm1b(EUCOMM)Wtsi}$
Dip2a$^{tm2b(KOMP)Wtsi}$	*Nup85*$^{tm1a(KOMP)Wtsi}$	*Zfp287*$^{tm1b(EUCOMM)Wtsi}$
Dlg3$^{tm1a(EUCOMM)Wtsi}$	*Nutm2*$^{tm2b(EUCOMM)Wtsi}$	*Zfp341*$^{tm1a(KOMP)Wtsi}$
Dlg4$^{tm1e(EUCOMM)Wtsi}$	*Nxn*$^{tm1b(EUCOMM)Wtsi}$	*Zfp365*$^{tm1a(KOMP)Wtsi}$
Dlk1$^{em1(IMPC)Wtsi}$	*Oaf*$^{tm1a(EUCOMM)Wtsi}$	*Zfp408*$^{tm1b(EUCOMM)Wtsi}$
Dmgdh$^{tm1a(KOMP)Wtsi}$	*Oog2*$^{tm1a(EUCOMM)Wtsi}$	*Zfp616*$^{tm1b(KOMP)Wtsi}$
Dnah17$^{tm1e(KOMP)Wtsi}$	*Orc1*$^{tm1a(KOMP)Wtsi}$	*Zfp658*$^{tm1b(EUCOMM)Wtsi}$
Dnajc8$^{tm1b(KOMP)Wtsi}$	*Os9*$^{tm1a(EUCOMM)Wtsi}$	*Zfp719*$^{tm1a(EUCOMM)Wtsi}$
Dnase1l2$^{tm1.1(KOMP)Wtsi}$	*Osbpl3*$^{tm1a(EUCOMM)Wtsi}$	*Zfp719*$^{tm1b(EUCOMM)Wtsi}$
Dnmt3a$^{tm1a(KOMP)Wtsi}$	*Otud7b*$^{tm1b(EUCOMM)Wtsi}$	*Zfp763*$^{em1(IMPC)Wtsi}$
Dnpep$^{tm1e(EUCOMM)Wtsi}$	*Pam16*$^{tm1b(EUCOMM)Wtsi}$	*Zfp791*$^{tm1a(KOMP)Wtsi}$
Dph6$^{tm1a(KOMP)Wtsi}$	*Pced1a*$^{tm1b(EUCOMM)Wtsi}$	*Zfp84*$^{tm1b(KOMP)Wtsi}$
Dpm1$^{tm1b(KOMP)Wtsi}$	*Mir122*$^{(tm1)Brd}$	*Zfp879*$^{tm2b(KOMP)Wtsi}$
Herc1$^{em3(IMPC)Wtsi}$	*(Cluster5N1*$^{)(tm1)Brd*}$	*Zfyve28*$^{tm1b(EUCOMM)Wtsi}$
(ClusterXN1)$^{tm1(Brd)*}$	*Mkrn2*$^{tm1b(KOMP)Wtsi}$	*Zranb1*$^{tm1a(EUCOMM)Hmgu}$
Arid1b$^{tm1b(EUCOMM)Hmgu}$		

*knockouts of multi-gene or regulatory regions

Cluster 5N1 mmu-mir-25 (ENSMUSG00000065394), mmu-mir-93 (ENSMUSG00000065527), mmu-mir-106b (ENSMUSG00000065514)

ClusterXN1 ENSMUSG00000070106, ENSMUSG00000065613 ENSMUSG00000065473, ENSMUSG00000076041 ENSMUSG00000077111, ENSMUSG00000065456
Cpgi81 CpG island 81, Chr1:23255875-23257106 bp

Supplementary Table 5: Key resources

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
CD3ε Functional grade purified, clone eBio500A2	eBioscience	16-0033-86; RRID: AB_842782
CD3ε BV421, clone 145-2C11	BD Biosciences	562600
CD3ε BV785, clone 145-2C11	BioLegend UK Ltd	100232
CD4 PE, clone RM4-5	BioLegend UK Ltd	00511; RRID: AB_312714
CD4 BV510, clone RM4-5	BioLegend UK Ltd	100553 RRID:AB_2561388
CD4 BV786, clone RM4-5	BD Biosciences	563331
CD5 APC, clone 53-7.3	BD Biosciences	550035
CD5 BV510, clone 53-7.3	BD Biosciences	563069
CD8a APC, clone 53-6.7	BioLegend UK Ltd	100712; RRID: AB_312750
CD8α AF700, clone 53-6.7	BD Biosciences	557959
CD8α APC-H7, clone 53-6.7	BD Biosciences	560182 RRID:AB_1645237
CD11b BV510, clone M1/70	BioLegend UK Ltd	101245
CD11b PE-Cy7, clone M1/70	BioLegend UK Ltd	101216 RRID:AB_312799
CD11c BV786, clone HL3	BD Biosciences	563735
CD19 BV421, clone ID3	BD Biosciences	562701
CD19 PE-CF594, clone ID3	BD Biosciences	562291 RRID:AB_11154223
CD19 PECY7, clone ID3	BD Biosciences	552854
CD21/35 FITC, clone 7G6	BD Biosciences	553818
CD21/35 PE, clone 7G6	BD Biosciences	552957
CD23 BV421, clone B3B4	BD Biosciences	562929
CD24 APC, clone M1/69	BD Biosciences	562349
CD25 APC, clone PC61	BD Biosciences	557192
CD25 PE, clone PC61	BioLegend UK Ltd	102008 RRID:AB_312857
CD28 Functional grade purified, clone 37.51	eBioscience	16-0281-86;RRID: AB_468923
CD43 PerCP-Cy5.5	BioLegend UK Ltd	121224
CD44 FITC, clone 1B11	BD Biosciences	553133
CD44 FITC, clone IM7	BD Biosciences	561859 RRID:AB_10894581

CD45 Alexa 700, clone 30-F11	BioLegend UK Ltd	103128 RRID:AB_493715
CD45 e450, clone 30-F11	eBioscience	48-0451-82
CD45 eVolve™ 605 (Qdot), clone 30-F11	eBioscience	83-0451-42
CD45 eFluor450, clone 30-F11	eBioscience	48-0451-82
CD45R (B220) PeCY7, clone RA3-6B2	BioLegend UK Ltd	103222
CD45R (B220) AF700, clone RA3-6B2	BD Biosciences	557957
CD62L PE-CF594, clone MEL-14	BD Biosciences	562404 RRID:AB_11154046
CD62L PerCP Cy5.5, clone MEL-14	BD Biosciences	560513
CD86 PECY7, clone GL1	BD Biosciences	560582
CD95 PECY7, clone Jo2	BD Biosciences	557653
CD103 PE, M290	BD Biosciences	557495
CD115 APC, clone AF598	BioLegend UK Ltd	135510 RRID:AB_2085221
CD138 BV650, clone 281-2	BioLegend UK Ltd	142517
CD161 (NK1.1) BV421, clone PK136	BioLegend UK Ltd	108732 RRID:AB_2562218
CD161 (NK1.1) BV650, clone PK136	BioLegend UK Ltd	108736
CD317 BV650, clone 927	BioLegend UK Ltd	127019
F4/80 PerCP-Cy5.5, clone BM8	BioLegend UK Ltd	123128
Fc block	BD Biosciences	553142
GITR PE, clone DTA-1	BD Biosciences	558119
GL-7 AF647, clone GL7	BD Biosciences	561529
Gr-1 AF700, clone RB6-8C5	BioLegend UK Ltd	108422
Ig HRP, polyclonal	Dako	P0447
IgG (H+L) FITC, polyclonal	Invitrogen	626511
IgG1 HRP, clone X56	BD Biosciences	559626
IgG2a HRP, clone R19-15	BD Biosciences	553391
IgD BV510, clone 11-26c.2a	BD Biosciences	563110
IgD PerCP-Cy5.5, clone 11-26c.2a	BioLegend UK Ltd	405710
IgD AF488, clone 11-26c.2a	BioLegend UK Ltd	405718
IgG1 PE, clone A85-1	BD Biosciences	550083
IgM BV42, clone RMM-1	BioLegend UK Ltd	406518
IgM BV786, clone R6-60.2	BD Biosciences	564028
KLRG1 BV421, clone 2F1	BD Biosciences	562897
KLRG1 PE-Cy7, clone 2F1	BioLegend UK Ltd	138416 RRID:AB_2561736
Ly-51 PE, clone BP-1	BD Biosciences	553735

Ly6B FITC, clone 7/4	AbD Serotec	MCA771FB RRID:AB_324596
Ly6C AF700, clone AL-21	BD Biosciences	561237
Ly6C PerCP-Cy5.5, clone HK1.4	BioLegend UK Ltd	128012 RRID:AB_1659241
Ly6G APC, clone 1A8	BD Biosciences	560599
Ly6G V450, clone 1A8	BD Biosciences	560603 RRID:AB_1727564
MHC II I-A/I-E PE, clone M5/114.15.2	BioLegend UK Ltd	107608 RRID:AB_313323
MHC II I-A/I-E AF647, clone M5/114.15.2	BioLegend UK Ltd	107618
MHC II I-A/I-E FITC, 2G9	BD Biosciences	553623
MHC II I-A/I-E AF647, clone M5/114.15.2	BioLegend UK Ltd	107618
Vγ5 (aka Vγ3) FITC, clone 536	BD Biosciences	553229
TCRβ PerCP-Cy5.5, clone H57-597	BioLegend UK Ltd	109228 RRID:AB_1575173
TCRδ PE CY7, clone GL3	BioLegend UK Ltd	118124
TCRδ APC, clone GL3	BioLegend UK Ltd	118116 RRID:AB_1731813
Chemicals, Peptides, and Recombinant Proteins		
10mM HEPES	Life Signalling Technologies	15630056
Collagenase	Sigma Aldrich - Roche	11088858001
DNAase	Sigma	DN25
RBC lysis buffer	eBioscience	00-4300-54
EDTA (0.5 M), pH 8.0	Life Technologies	AM9261
Prolong Gold Mounting Medium	New England Biolabs	9071S
Zombie NIR Fixable Viability Kit	Biolegend	423106
BD FACSDiva CS&T Research Beads	BD Biosciences	655051
Ammonium thiocyanate	Sigma	A7149-100G
Nair™ moisturizing hair removal cream	Church & Dwight Co.	N/A
Acetone	VWR	20067-320
Fetal Bovine Serum	Gibco	FBS
Fetal Bovine Serum	Hyclone laboratories - Biosera	FB-1001/500

RPMI 1640	GIBCO - life technologies	21875034
RPMI 1640 (no phenol red)	GIBCO - life technologies	32404014
PBS 10x (neg for CA2+ and Mg2+)	Gibco	14200-067
PBS 10x (with calcium & Magnesium)	Gibco	14080-048
PBS, D'Beccos	GIBCO - life technologies	14190094
D-MEM (HG)	GIBCO - life technologies	41966029
DPBS	Sigma-Aldrich	D8662
Water	Sigma-Aldrich	W3500
Mouting Medium Dropper Vial 5mL	A. Menarini Diagnostics Ltd.	38015
2-mercaptoethanol	GIBCO Invitrogen	31350010
L-Glutamine	GIBCO Invitrogen	25030024
Recombinant murine IL-2	Peprotech	212-12-100
Penicillin/Streptomycin	Sigma-Aldrich	P4333
Sodium Pyruvate MEM	Sigma-Aldrich	11360039
Dextran sulfate, sodium salt	Affymetrix, Inc.	14489; CAS# 9011-18-1
Formaldehyde 4% solution	VWR international ltd	9713.5000
BSA	Sigma-Aldrich	A9056
Sigmafast	Sigma-Aldrich	P9187
LB	Oxoid	CM1018
Ampicillin	Roche	10 835 242 001
Tween 20	Sigma-Aldrich	P1379
Critical Commercial Assays		
Zenit ANA HEp-2 Cells (12 wells)	A. Menarini Diagnostics Ltd.	37806
FITC – QC Slide	A. Menarini Diagnostics Ltd.	38015
Cytotox 96 non-radioactive assay	Promega UK Ltd	G1780
Deposited Data		
3i statistical analysis	This study	www.immunophenotype.org
Raw and analyzed data	This study	www.immunophenotype.org

Experimental Models: Cell Lines		
P815 mastocytoma cell line	ATTC	TIB-64
HEp-2 cell lines, coated on slides	A. Menarini Diagnostics Ltd.	37806
Experimental Models: Organisms/Strains		
C57BL/6N wild type control mice	WTSI	
Knockout mouse strains as detailed in supplementary table 1	WTSI	
Salmonella typhimurium M525 :: TetC	Gordon Dougan, WTSI	
Trichuris muris	Richard Grencis, University of Manchester	
Equipment		
Scil Vetabc hematology analyser	Horiba	http://www.horiba.com/uk/medical/products/animal-healthcare/haematology/scil-vet-abc-details/scil-vet-abc-12687/
BD LSR II flow cytometer (Blood)	BD Biosciences	RRID:SCR_002159; http://www.rockefeller.edu/fcrc/pdf/BD_LSRII_Brochure_SJ-0142-00.pdf
BD LSR Fortessa X-20 (Spleen, MLN, and bone marrow)	BD Biosciences	http://www.bdbiosciences.com/us/instruments/research/cell-analyzers/bd-lsrfortessa-x-20/m/1519232/overview
Leica SP2 confocal microscopes, 40x 1.25 NA oil immersion lens and 405 nm, 488 nm and 633 nm lasers (Ear epidermis)	Leica	https://www.leica-microsystems.com/products/confocal-microscopes/details/product/leica-tcs-sp2/

Leica SP5 confocal microscopes, 40x 1.25 NA oil immersion lens and 405 nm, 488 nm and 633 nm lasers (ear epidermis)	Leica	https://www.leica-microsystems.com/products/confocal-microscopes/details/product/leica-tcs-sp5/
Nikon wide-field TE2000U Microscope (ANA)	Nikon	TE2000U
Deltavision Elite widefield system based on an Olympus microscope, LED light source and CoolSNAP HQ2 camera (ANA)	GE Healthcare Life Sciences, Olympus	https://www.gelifesciences.com/en/us/shop/deltavision-elite-high-resolution-microscope-p-04420
Zeiss AxioPlan Microscope with a Plan Neofluar 5x/0.15 Ph1 objective and Moti Cam 10 camera (DSS)	Zeiss	https://www.zeiss.com/microscopy/int/home.html?gclid=EAIaIQobChMIj7KRv-mH4QIVybHtCh0C3w_OEAAYASAAEgJ2afD_BwE
Software and Algorithms		
R version 3.3.1 and general data analysis packages (data.table, ggplot2, dplyr, igraph, MASS)	The R project for statistical computing	www.r-project.org
PhenStat_2.8	BioConductor	www.bioconductor.org
RStudio 1.0.136	RStudio	https://www.rstudio.com
R code for reference range analysis, assessment of false positive rate	Anna Lorenc	available on request
Flow Jo v1.10	Treestar	RRID:SCR_008520; http://www.flowjo.com
Cytoscape 3.6.1	Cytoscape	www.cytoscape.org
BD DIVA 7.0	BD Biosciences	RRID:SCR_001456; http://www.bdbiosciences.com/instruments/software/facsdiva/index.jsp
flowClean	Ryan Brinkman	Fletez-Brant et al 2016
UFO	Ryan Brinkman	available on request
flowDensity	Ryan Brinkman	Malek et al 2015

PRISM 6	Graphpad software	http://www.graphpad.com/scientific-software/prism/
Definiens developer	Definiens	www.definiens.com
ANA assay Fiji/ImageJ macro	Katherine Bull	available on request
ANA assay Python scoring script	Katherine Bull	available on request
Microsoft Excel 2010	Microsoft	https://www.microsoftstore.com/store/msuk/en_GB/home
Deposited Data		
3i statistical analysis	This study	www.immunophenotype.org
Raw and analyzed data	This study	www.immunophenotype.org
Other		
30µm CellTrics filters	Partec Cell Trics	04-0042-2316
96 Well Clear V-Bottom Not Treated Polypropylene Microplate, Nonsterile	SLS	353263
Microtube MaxyClear PP clear 1.7mL (Axygen)	Fisher	12756799
C-Tubes	Miltenyi Biotec	130-096-334
Superfrost R Plus #72, 26X76X1mm (75 pieces)	VWR	631-0108
Cover Glass 22 X 40 Mm No. 1,5	VWR	631-1370

Figure 1


A
WTSI / IMPC general screen
3i steady state screen
3i challenge screen
>3800 mice
>2100 mice
>4500 mice
>2300 mice
>500 ko lines
>1 million parameters
>3600 mice
>4000 mice
>1700 mice
>4500 mice
>10000 mice
>4000 mice
Bone marrow 3F3M
Ear epidermis 2F2M
Antinuclear antibodies 3F3M
Cytotoxic T Cell function 2F2M
Expanded into a comprehensive steady state and challenge screen
DSS colitis challenge 2F2M or 4M
Influenza 3F3M
Trichuris muris 6F
Salmonella typhimurium 4F4M
Blood 7F7M
Spleen 3F3M
Mesenteric lymph node 3F3M
Hair
Skin
Senses
Neurology
Cardio-vascular system
Musculo-skeletal system
Metabolism
Salmonella typhimurium
Immunology
Blood
Viability
Fertility
WTSI/IMPC general screen
B
Population frequencies % of CD45+ cells
Log2 fold change female / male
Coefficient of variation
Sex
Female
Male
-log10 p-value
Lineage
αβ T cell
B cell
γδ T cell
Myeloid
NK cell
NKT cell
C
PB
BM
% of CD45+ cells
Females
Males
Female neutrophils
Male neutrophils
Females (F)
Males (M)
F
M
Hardy Fraction A
Hardy Fraction C
D
Females
Males
PCA 2 (16% explained variation)
PCA 1 (18% explained variation)

Figure 2

A Males



B Males versus females



C

Males



Females



Bone marrow parameters

Blood parameters

Spleen parameters

MLN parameters

positive correlation

negative correlation

Alb	Albumin
Chol	Cholesterol
Cl	Chloride
Fe	Iron
Frct	Fructose
Gluc	Glucose
Glyc	Glycerin
Hct	Haematocrit
Hdl	HDL cholesterol
Hgb	Haemoglobin
Ins	Insulin
Ldl	LDL cholesterol
Mcv	Mean corpuscular volume
Mpv	Mean platelet volume
Na	Sodium
nFFA	Non-esterified free fatty acids
Rbc	Red blood cell count
Rdw	Red blood cell distribution width
Thyrx	Thyroxin
Wght	Weight

1 Total T cells
2 αβ T cells
3 CD8+ T cells
4 Effector CD8+ T cells
5 Resting CD8+ T cells
6 Naïve CD8+ T cells
7 CD4+ T cells
8 Effector CD4+ T helper cells
9 Resting CD4+ T helper cells
10 Klrg1+ CD4+ T helper cells
11 Treg cells
12 Effector Treg cells
13 Resting Treg cells
14 Klrg1+ Treg cells
15 CD5+ γδ T cells
16 Total NKT cells
17 Ly6C+ NKT cells
18 Effector CD4- NKT cells
19 Resting CD4- NKT cells
20 Total NK cells
21 Klrg1+ NK cells
22 Immature NK cells
23 Mature NK cells
24 Ly6C+ mature NK cells
25 Total B cells
26 Follicular B cells
27 Marginal zone B cells
28 Memory B cells
29 Total B cell precursors
30 Hardy Fraction A
31 Hardy Fraction B
32 Granulocytes (BM)
33 Granulocytes
34 Neutrophils
35 Eosinophils
36 Monocytes
37 Total DC
38 Conventional DC (cDC)
39 CD11b-high cDC
40 CD11b-low cDC
41 CD103+ CD11b-low cDC
42 Late germinal centre B cells

Figure 3


Allele
Blood
SPLN
MLN
BM
Ear
CTL
ANA
DSS colitis
Salmonella
Influenza
Trichuris
Mir 122(tm1)Brd
1700034J05Riktm1a(KOMP)Wtsi
4932431P20Rikem1(IMPC)Wtsi
Actl10tm1a(EUCOMM)Wtsi
Adamts3tm1b(KOMP)Wtsi
Adap1tm1a(EUCOMM)Wtsi
Adcy9tm1b(EUCOMM)Wtsi
Adgrd1tm1b(EUCOMM)Wtsi
Aicdatm1b(EUCOMM)Hmgu
Alpk1em1(IMPC)Wtsi
Ap4e1tm1b(KOMP)Wtsi
Arhgap17tm1b(EUCOMM)Wtsi
Arhgef1tm1a(EUCOMM)Wtsi
Arpc1btm1a(EUCOMM)Wtsi
Atp5etm1b(EUCOMM)Wtsi
Atxn10tm1b(KOMP)Wtsi
Atxn3tm1a(KOMP)Wtsi
Bach2tm1a(EUCOMM)Wtsi
Bai1tm2a(EUCOMM)Wtsi
Bivmtm1b(KOMP)Wtsi
Brd2em1(IMPC)Wtsi
Camkmttm1b(EUCOMM)Wtsi
Camsap3tm1a(EUCOMM)Wtsi
Capza2tm1b(KOMP)Wtsi
Cbr2tm1b(EUCOMM)Hmgu
Ccdc6em1(IMPC)Wtsi
Cfap61tm2a(EUCOMM)Wtsi
Cgrrftm1b(KOMP)Wtsi
Clpptm1a(EUCOMM)Wtsi
Cluster5N1(tm1)Brd
Cnbd1tm1b(EUCOMM)Wtsi
Cnot4tm1b(EUCOMM)Wtsi
Cog6tm1a(EUCOMM)Wtsi
Col4a3bptm1a(KOMP)Wtsi
Csmd1em1(IMPC)Wtsi
Ctr9tm1b(EUCOMM)Wtsi
Cttnbp2tm1b(KOMP)Wtsi
Cxcr1tm1a(EUCOMM)Wtsi
Cxcr2tm1a(EUCOMM)Wtsi
D6Wsu163etm1b(EUCOMM)Wtsi
Daptm1a(KOMP)Mbp
Dbn1tm1b(KOMP)Wtsi
Dcbld2tm1a(KOMP)Wtsi
Dctn4em1(IMPC)Wtsi
Defb14tm1b(KOMP)Wtsi
Dennd1btm1a(EUCOMM)Hmgu
Dffbem1(IMPC)Wtsi
Dip2atm2b(KOMP)Wtsi
Dph6tm1a(KOMP)Wtsi
Duoxa2tm1b(KOMP)Wtsi
Mir210 (tm1)Brd
Enthd2tm1b(KOMP)Wtsi
Fam122ctm1b(EUCOMM)Wtsi
Fam160a1tm1b(EUCOMM)Wtsi
Fam47etm1a(EUCOMM)Wtsi
Fbf1tm1a(EUCOMM)Wtsi
Fbxw26tm1b(KOMP)Wtsi
Galnt18tm1b(KOMP)Wtsi
Gdatm1a(KOMP)Wtsi
Gimap6tm1a(KOMP)Wtsi
Gm12253tm1a(KOMP)Wtsi
Gm13125tm1b(KOMP)Wtsi
Gm16515tm1b(EUCOMM)Wtsi
Gm5544tm1a(KOMP)Wtsi
Gmdstm1a(KOMP)Wtsi
Grsf1tm1b(EUCOMM)Wtsi
Gt(ROSA)26SorROSA26_Dre_C03
H13tm1b(KOMP)Wtsi
Hao2em1(IMPC)Wtsi
Hbs1ltm1a(KOMP)Wtsi
Herc1em3(IMPC)Wtsi
Ifnar1tm2a(EUCOMM)Wtsi
Il1r2tm1a(EUCOMM)Wtsi
Il27tm1b(EUCOMM)Wtsi
Irak1tm1b(EUCOMM)Hmgu
Irf5tm1e(EUCOMM)Wtsi
Klhl30tm1a(KOMP)Wtsi
Krt31tm1e(KOMP)Wtsi
Krt83tm1b(KOMP)Wtsi
Ldlrad4tm1b(EUCOMM)Wtsi
LmnaG609G
Lrrc8dtm1a(EUCOMM)Wtsi
Mbl2em1(IMPC)Wtsi
Mir96tm2.2(IMPC)Wtsi
Mkrn2tm1b(KOMP)Wtsi
Myo9tm1b(EUCOMM)Wtsi
Nacc2tm2b(EUCOMM)Wtsi
Ncf2tm1a(EUCOMM)Wtsi
Nebltm1b(EUCOMM)Wtsi
Nipsnap3atm1b(KOMP)Wtsi
Nrbp1tm3b(EUCOMM)Wtsi
Oaftm1a(EUCOMM)Wtsi
Os9tm1a(EUCOMM)Wtsi
Pclaftm1a (EUCOMM)Wtsi
Pdcd2tm1b(EUCOMM)Wtsi
Pepdtm1a(KOMP)Wtsi
Prkab1tm1b(KOMP)Wtsi
Prrt2tm1a(KOMP)Wtsi
Pth1rtm1a(EUCOMM)Wtsi
Pycr2tm1a(EUCOMM)Wtsi
Rbm33tm1b(EUCOMM)Wtsi
Repin1tm1a(EUCOMM)Wtsi


Allele
Blood
SPLN
MLN
BM
Ear
CTL
ANA
DSS colitis
Salmonella
Influenza
Trichuris
Rnf10tm1b(KOMP)Wtsi
Rundc1tm1b(KOMP)Wtsi
Rwdd1tm1b(KOMP)Wtsi
Scaf11em1(IMPC)Wtsi
Sept10tm1a(KOMP)Wtsi
Setd5tm1a(EUCOMM)Wtsi
Sgsm1tm1b(EUCOMM)Wtsi
Sik3tm1a(EUCOMM)Hmgu
Slc9a3r2tm2a(EUCOMM)Hmgu
Smg9tm1b(EUCOMM)Wtsi
Spink14tm1e(KOMP)Wtsi
Srsf7tm1a(EUCOMM)Wtsi
Supt5tm2a(KOMP)Wtsi
Tcf7l2tm1a(EUCOMM)Wtsi
Tchptm1a(EUCOMM)Wtsi
Timmdc1tm1b(EUCOMM)Wtsi
Tmem126atm1a(EUCOMM)Wtsi
Tmem127tm1(KOMP)Wtsi
Traf2tm1a(EUCOMM)Wtsi
Allele
Blood
SPLN
MLN
BM
Ear
CTL
ANA
DSS colitis
Salmonella
Influenza
Trichuris
Trappc10tm1b(KOMP)Wtsi
Trappc9tm1a(EUCOMM)Wtsi
Trem1tm1(KOMP)Vlcg
Trim56tm1a(EUCOMM)Wtsi
Trmt2atm2b(EUCOMM)Wtsi
Ubxn10tm1b(EUCOMM)Wtsi
Usp30tm2b(EUCOMM)Hmgu
Vps13atm1b(EUCOMM)Wtsi
Vwa3atm1b(KOMP)Wtsi
Wactm1b(EUCOMM)Wtsi
Wdtc1tm1a(KOMP)Wtsi
Xkrxtm1b(EUCOMM)Wtsi
Xpnpep1tm1a(KOMP)Wtsi
Ydjctm1(KOMP)Wtsi
Zbed5tm1b(EUCOMM)Wtsi
Zfp408tm1b(EUCOMM)Wtsi
Zfp616tm1b(KOMP)Wtsi
Zfp763em1(IMPC)Wtsi
Zfp879tm2b(KOMP)Wtsi

Figure 4

A



B Nacc2 -/-





C Dph6 -/-



Figure 5


A
Blood
Spleen
MLN
BM
Epidermis
CTL
ANA
DSS colitis
Salmonella
Influenza
Trichuris
Haematology
Plasma Chemistry
Homozygous viability
Weight curve
X-ray imaging
Dysmorphology
Heart weight
Body Composition (DEXA)
Indirect Calorimetry
Glucose Tolerance
Insulin
Neurological Assessment
Grip Strength
Auditory Brainstem Response
Bach2tm1a(EUCOMM)Wtsi
Duoxa2tm1b(KOMP)Wtsi
B Blood immune cell subsets in Duoxa2-/- mice
Duoxa2-/- female
Duoxa2-/- male
wt female
wt male
Normalised cell subset frequency (populations frequency / dataset mean)
Total T cells
ab T cells
CD4+ ab T cells
CD8+ ab T cells
gd T cels
NKT cells
NK cells
Treg cells
Effector CD4+ th cells
Effector CD8+ T cells
KLRG1+ NK cells
KLRG1+ CD4+ T cells
KLRG1+ CD8+ T cells
B cells
IgD+ Mature B cells
Total monocytes
Ly6C+ monocytes
Ly6C- monocytes
Neutrophils
Eosinophils
C Spleen immune cell subsets in Bach2-/- mice
Not Significant
Novel
Published
Log2 fold change Ko / wt
D Cytotoxic T cell lysis in Bach2-/- mice
% lysis
Female
Male
10:1
5:1
2.5:1
1.25:1
0.625:1
0.3125:1
Ratio CTL:Target
E DSS-induced colitis in Bach2-/- mice
Relative Weight
Female
Male
Days of Treatment

Figure 6


A
challenge phenotype
yes
no
no
yes
steady state phenotype
54
22
390
64
No. of affected immune flow parameters
0
5
10
20
40
80
100
No. of Pubmed hits
0-5
6-10
11-15
16-30
31-50
51-100
101-200
201-500
>500
B
p=0.023
66
36
269
83
0.9 cut-off
Intolerance to loss of function (pLI)
1.00
0.75
0.50
0.25
0.00
3i genes without immune phenotype (n = 335)
3i genes with immune phenotype (n = 119)
All ExAC genes (n = 18852)
p=0.048
66
17
269
36
0.9 cut-off
3i genes without immune phenotype (n = 335)
3i genes with steady-state phenotype only (n = 53)
C
challenge phenotype
yes
no
no
yes
steady state phenotype
19
12
35
10
91
27
299
37
No. of affected immune flow parameters
0
5
10
20
40
80
100
non- immune phenotype:
no
yes
D
proportion of genes
1.00
0.75
0.50
0.25
0.00
NO (n=368)
YES (n=131)
Immune phenotype
with immune OMIM entry
with immune GWAS association
other tested genes
GWAS
28
21
340
110
p<0.0095
OMIM
2
7
368
124
p<0.0017

Figure 7


A
Population B
Population A
B
Mature NK cells % of NK cells
Total NK cells % of CD45
Genotype
Arhgef1:Hom
Arpc1b:Hom
Gmds:Hom
Pclaf:Hom
Naive CD8+ T cells % of CD8 T cells
Effector CD4+ Th cells % of CD4+ Th cells
Genotype
Cog6:Hom
Dph6:Hom
Duoxa2(b):Hom
Gmds:Hom
C
Impacts of genes on correlations between organs
correlations (%)
822 290
20 0
14 0
13 1
9 1
23 4
121 24
110 22
119 26
11 3
17 5
17 6
24 9
8 3
83 36
27 12
48 23
48 31
16 20
25 61
Total
Prkab1
Irf5
Il27
Gimap6
Arhgef1
Dph6
Duoxa2
Sik3
Aicda
Pepd
Clpp
Pclaf
Arhgap17
Cog6
Arpc1b
Gmds
Tmem127
Cxcr2
Bach2
preserving
breaking
Impacts of genes on correlations within organs
correlations (%)
919 341
32 0
17 0
12 0
36 2
15 1
72 10
102 15
89 15
28 5
20 4
9 2
8 2
45 12
21 6
89 27
70 24
19 13
95 98
73 101
Total
Prkab1
D6Wsu163e
Setd5
Arpc1b
Clpp
Duoxa2
Dph6:Hom
Cxcr2:Hom
Arhgef1
Pepd
Rwdd1
Zfp616
Pclaf
Hbs1l
Sik3
Gmds
Tmem127
Bach2
Cog6
preserving
breaking
D
Examples of shape breaking in Dph6-/- and Cog6-/- lines
wt
Dph6-/-
Cog6-/-
BM
Spleen
Blood
MLN
αβ T cell
B cell
γδ T cell
Myeloid
NK cell
NKT cell
All correlations
Preserved correlations
Broken correlations
E
Correlation-breaking and non-immune phenotypes
469 88
1272 543
correlations (%)
preserved
breaking
p<0.001
immune only
immune + non-immune
F
Correlation-breaking and challenge phenotypes
1044 250
697 381
correlations (%)
preserving
breaking
p<0.001
steady state only
steady state + challenge

Supplementary figure 1

A

Tests performed at WTSI	
Viability / Fertility	Viability Fertility Recessive lethality
Anatomy	X-ray imaging Dysmorphology Hair dysmorphology Hair Follicle Cycling Heart weight
Metabolism	Body Composition (DEXA) Indirect Calorimetry Glucose Tolerance Insulin
Immune System	Blood cytometric analysis Salmonella challenge Citrobacter challenge
Other	Modified Shirpa Grip Strength Erythrocyte Micronuclei Auditory Brainstem Response Plasma Chemistry Haematology

B



C



Confocal image of ear epidermis

Objects identified in raw image

Close-up of 3D reconstructed cell

D



E


% of initial body weight
110
100
90
80
70
0
2
4
6
8
10
Day
1.5% DSS
H_2O
Arhgef1-/-
WT


*
Histopathology Score
12
10
8
6
4
2
0
WT
Arhgef1 -/-


wt
Arhgef1-/-
Mid colon
Distal colon

F


WT Baseline : CD4+ T helper cells - % of CD45+ - Males
Assay Date
2014
2015
2016
June
July
August
September
October
November
December
January
February
March
April
May
June
July
August
Septe..
October
November
Decem..
January
February
97.5 Percentile
Median
2.5 Percentile
Variable of Interest
CD4+ T helper cells - % of CD45+
WT Baseline : CD4+ T helper cells - % of CD45+ - Females

G


Coefficient of variation
1.0
0.5
0
0.1
10
mean population size (% of CD45), log10
Lineage
ab T cell
B cell
gd T cell
Myeloid cell
NK cell
NKT cell
No of gates
7
6
5
4
3
2

H


Coefficient of variation (%)
300
200
100
0
Log2 fold change female /male
0.50
0.25
0.00
-0.25
Average volume of LC
Ratio of Vg5+ DETC/LC
Average volume of Vg5+ DETC
Average branch length of LC
Average roundness of LC
Average no of branches on LC
Average branch length of Vg5+ DETC
DETC coverage
Average roundness of Vg5+ DETC
Average no of branches on Vg5+ DETC
Count of Vg5+ DETC not contacting LC
Vg5+ Dendritic epidermal T cell (DETC) count
Ratio of contacting/not contacting Vg5+ DETC
Count of Vg5+ DETC contacting LC
Langerhans cell (LC) count
10:1 CTL value
5:1 CTL value
2.5:1 CTL value
1.25:1 CTL value
0.3125:1 CTL value
0.625:1 CTL value
Epithilium histo
Area histo
Total histo score
Lamina propria histo
Severe markers histo
ANA Score
Organ
CTL
DSS
Ear
-log10 p-value

Supplementary figure 2

A Females



B



positive correlation

negative correlation

Alb	Albumin
Alp	Alkaline phosphatase
Alt	Alanine aminotransferase
Amy	α-Amylase
Ast	Aspartate aminotransferase
Ca	Calcium
Cl	Chloride
Chol	Cholesterol
Ck	Creatinine kinase
Crea	Creatinine
Fe	Iron
Fruct	Fructosamine
Gluc	Glucose
Glyc	Glycerol
Hct	Hematocrit
Hdl	HDL cholesterol
Hgb	Hemoglobulin
Ins	Insulin
K	Potassium
Ldl	LDL cholesterol
Mch	Mean corpuscular hemoglobin
Mchc	Mean cell hemoglobin concentration
Mcv	Mean corpuscular volume
Mg	Magnesium
Mpv	Mean platelet volume
Na	Sodium
nFFA	Free fatty acids
P	Phosphorus
Rbc	Red blood cell count
Rdw	Red blood cell distribution width
Tbil	Total bilirubin
Thyrx	Thyroxine
Tp	Total protein
Trigs	Triglycerides
Urea	Urea
Whgt	Weight

Females



Supplementary figure 3



Supplementary figure 4.









E.


KLRG1+ NK cells
57.5
Count
KLRG1 PE-Cy7
singlets
94.4
FSC-H
FSC-A
Leukocytes
100.0
SSC-A
CD45 AF700
gd T cells
1.23
gdTCR APC
abTCR perCP-Cy5.5
NK cells
2.76
NKT cells
0.18
TCRab T cells
25.5
NK1.1 BV421
CD4 T cells
59.6
CD8 T cells
39.6
CD4 BV510
CD8 APC-cy7
CD8 Teff
1.07
CD44 FITC
CD62L PE-Cf594
KLRG1+ CD8 T cells
0.42
CD4 Teff
5.08
CD62L PE-CF594
KLRG1+ CD4 T cells
0.71
KLRG1 PE-Cy7
Tregs
8.64
CD25 PE

F.


IgD+ B cells
78.6
Count
IgD BV510
singlets
95.1
FSC-H
FSC-A
Leukocytes
100.0
SSC-A
CD45 AF700
B cells
50.2
not B
49.5
CD19 PE-CF594
Ly6B FITC
Neutrophils
12.9
Not neutrophils
87.1
Ly6B AF700
Ly6G BV421
Eosinophils
4.19
CD11b PE-Cy7
Monocytes
9.51
CD115 APC
CD11b PE-Cy7
Ly6Chi monocytes
58.4
Q2
4.01
Ly6Clo monocytes
33.1
Q3
4.48
Ly6C PerCP-Cy5.5
MHC ia/ie PE